Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 2 of 78TABLE OF CONTENTS
List of Abbreviations ................................................................................................................................. 7 
1. INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ............. 8
1.1 Background ................................................................................................................................... 8 
1.2 RenewTM NCP-5 ............................................................................................................................. 9 
1.3 Mechanism of Action .................................................................................................................. 10 
1.4 Implications for Cerebral Blood Flow .......................................................................................... 11 
2. DETERMINATION OF ELIGIBILITY ............................................................................................. 12
2.1 Assessment of Cognition ............................................................................................................. 13 
2.2 Imaging and Physiological Assessment ....................................................................................... 14 
2.2.1 Imaging Studies ................................................................................................................... 14 
2.2.2 Hippocampal Volume as a Biomarker of Disease Modification .......................................... 14 
2.2.3 Regional Cerebral Blood Flow and White Matter Hyperintensities as Potential Biomarkers 
of Disease ............................................................................................................................................ 15 
2.2.4 Physiological Assessments .................................................................................................. 16 
2.3 Blood studies ............................................................................................................................... 17 
3. RATIONALE ...................................................................................................................................... 17
3.1 Potential Risks ............................................................................................................................. 18 
3.2 Potential Benefits ........................................................................................................................ 20 
4. STUDY OBJECTIVES AND PURPOSE ........................................................................................... 20
5. STUDY DESIGN AND ENDPOINTS ............................................................................................... 21
5.1 Study Design................................................................................................................................ 21 
5.2 Endpoints .................................................................................................................................... 23 
5.2.1 Primary Endpoint ................................................................................................................ 23 
5.2.2 Secondary safety and effectiveness endpoints ................................................................... 24 
5.2.3 Payor-based endpoints ....................................................................................................... 25 
5.2.4 Exploratory endpoints ......................................................................................................... 26 
6. STUDY ENROLLMENT AND WITHDRAWAL ............................................................................. 28
6.1 Inclusion Criteria ......................................................................................................................... 28 
6.2 Exclusion criteria ......................................................................................................................... 29 
6.3 Recruitment and Retention ........................................................................................................ 31 
6.4 Withdrawal or Termination ........................................................................................................ 31 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 3 of 787. DEVICE .............................................................................................................................................. 32
7.1 Device Description ...................................................................................................................... 32 
7.2 Acquisition of Device................................................................................................................... 33 
7.3 Storage and Stability ................................................................................................................... 33 
7.4 Preparation ................................................................................................................................. 33 
7.5 Dosing and Administration ......................................................................................................... 33 
7.6 Duration of Therapy .................................................................................................................... 35 
7.7 Tracking of Therapy..................................................................................................................... 35 
8. STUDY PROCEDURES AND SCHEDULE ..................................................................................... 36
8.1 Study Specific Procedures ........................................................................................................... 36 
8.2 Laboratory Evaluations ............................................................................................................... 40 
8.3 Study Schedule ............................................................................................................................ 41 
8.4 Study Visits .................................................................................................................................. 43 
8.4.1 Screening (-35 to -7 days prior to baseline) ........................................................................ 43 
8.4.2 Baseline Visit (Day -14 – Day -1) ......................................................................................... 43 
8.4.3 Randomization/First Treatment Day (Day 1) ...................................................................... 44 
8.4.4 Weeks 1-6 ........................................................................................................................... 44 
8.4.5 Week 6 – Day 42 (+/- 2 days) .............................................................................................. 45 
8.4.6 Weeks 7-12 ......................................................................................................................... 45 
8.4.7 Week 12 – Day 84 (+/- 2 days) ............................................................................................ 45 
8.4.8 Weeks 13-18 ....................................................................................................................... 46 
8.4.9 Week 18 – Day 126 (+/- 2 days) .......................................................................................... 46 
8.4.10 Weeks 19-24 ....................................................................................................................... 47 
8.4.11 Week 24 – Day 168 (+/- 2 days) .......................................................................................... 47 
8.4.12 Month 9 (Week 36) – Day 252 (+/- 7 days) ......................................................................... 48 
8.4.13 Month 12/Study Termination – Day 365 (+/- 7 days) ......................................................... 49 
8.4.14 Early Termination Visit ........................................................................................................ 49 
8.4.15 Study Disposition ................................................................................................................ 49 
8.5 ONGOING ASSESSMENTS ............................................................................................................ 50 
8.5.1 Concomitant Medications, Treatments and Exercise ......................................................... 50 
8.5.2 Laboratory Evaluations  .................................................................................................... 50 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 4 of 788.5.3 Vital signs  ............................................................................................................................ 51 
8.5.4 Physical examination  .......................................................................................................... 51 
8.5.5 Electrocardiogram  .............................................................................................................. 51 
9. SAFETY ASSESSMENTS  ............................................................................................................... 51
9.1 Adverse  Events  ........................................................................................................................... 51 
9.2 Adverse Event Assessment ......................................................................................................... 53 
9.3 Adverse Event Reporting ............................................................................................................ 54 
9.3.1 Adverse Event Reporting .................................................................................................... 54 
9.3.2 Reporting of Unanticipated (Serious) Adverse Device Effects, Serious Adverse Events, or 
Device Deficiencies ............................................................................................................................. 54 
9.4 Emergency procedure for unblinding ......................................................................................... 55 
9.5 Instructions for completing adverse effect case report forms  ................................................. 55 
10. ADMINISTRATIVE PROCEDURES  ........................................................................................... 55
10.1 Changes to the protocol .............................................................................................................. 55 
10.2 Monitoring procedures  .............................................................................................................. 55 
11. STATISTICAL CONSIDERATIONS  .............................................................................................. 55
12. DOCUMENT RETENTION  ............................................................................................................. 56
13. DATA FLOW ..................................................................................................................................... 56
13.1 Source Data, Record Keeping, Handling, and Retention at the Sites ......................................... 57 
13.2 Data Transmission, Data Handling, Storage, Retention and Archiving at DCC ........................... 58 
14. AUDITING PROCEDURES  .............................................................................................................. 60
15. PUBLICATION OF RESULTS  ......................................................................................................... 60
15.1 Disclosure and C onfidentiality .................................................................................................... 61 
16. DISCONTINUATION OF STUDY  ................................................................................................... 61
17. ETHICS AND GOOD CLINICAL PRACTICE  .............................................................................. 61
17.1 Institutional Review Board/Independent Ethics Committee  .............................................. 61 
18. REFERENCE LIST  ............................................................................................................................ 63
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 5 of 78LIST OF FIGURES
Figure 1: A model for cognitive impairment, cerebral vascular health, and potential points at which 
RenewTM NCP-5 could play a positive role. ................................................................................................. 18 
Figure 2: Laboratory evaluations to be performed ..................................................................................... 50 
Figure 3: RenewTM NCP-5 - 1001 Data Flow ................................................................................................ 57 
Table 1: RenewTM NCP-5 Treatment Schedule ............................................................................................ 41 
Table 2: RenewTM NCP-5 Visit Schedule ...................................................................................................... 41 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 6 of 78APPROVAL SIGNATURE
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due 
to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type (Renew ™ NCP-5-1001) 
The signature below represents my review and approval of: 
Protocol Version 3.1   
Site Principal Investigator:  __________________________________________ 
Date:   __________________________________________  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 7 of 78LIST OF ABBREVIATIONS
The following abbreviations are used in this study protocol. 
Abbreviation or specialist term Explanation
AD Alzheimer’s Disease 
ADAS-Cog Alzheimer’s Disease Assessment Scale Cognitive 
ADCS-ADL Alzheimer's Disease Co-op Study-Activities and Daily Living 
ADCS-CGIC Alzheimer's Disease Co-op Study-Clinical Global Impression of Change 
ADR Adaptive Design Report 
APOE Apolipoprotein E 
BPM Beats per Minute 
CBF Cerebral Blood Flow 
CBFV Cerebral Blood Flow Velocity 
CHF Congestive Health Failure 
CRP C-reactive protein 
CVR Cerebrovascular reactivity 
DD Device Deficiency 
DSM IV Diagnostic & Statistical Manual of Mental Disorders, 4th ed. 
ECG Electrocardiography 
ECP External Counterpulsation 
EMA European Medicines Agency 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
HRU Health Resource Utilization 
ICH International Conference on Harmonisation  
IDE Investigational Device Exemption 
INR International normalized ratio 
LDL-C Low Density Lipoprotein Cholesterol 
LM Logical Memory 
LP-PLA2 Lipoprotein-associated phospholipase A2 
MCI Mild Cognitive Impairment 
MMSE2 Mini Mental State Examination – Second Edition 
MOCA Montreal Cognitive Assessment 
MPO Myeloperoxidase Enzyme 
MRI Magnetic Resonance Imaging 
NIA National Institute of Aging 
NPI Neuropsychiatric Inventory 
NSR Non-significant Risk 
PSI Pounds per Square Inch 
SPECT Scan Single Photon Emission Computed Tomography 
TUG Timed Up and Go Test 
vADAS-Cog Vascular Dementia Assessment Scale Cognitive Subscale 
VD Vascular Dementia 
WMH White Matter Hyperintensities 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 8 of 781.INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE 
1.1 Background
Alzheimer’s Disease (AD) is an acquired cognitive and behavioral impairment of sufficient severity that it 
markedly interferes with social and occupational functioning and is the most common cause of 
dementia (Sun, Zhu, et al., 2007). Specifically, AD is a progressive neurodegenerative disorder 
characterized by the gradual onset of dementia. AD is well established to be degenerative, progressive, 
and irreversible, as the disease interferes with the neuron-to-neuron communication at synapses and 
contributes to cell death (Sun, Zhu, et al., 2007). No currently available treatment for AD slows or stops 
the damage to neurons that causes AD symptoms and eventually makes the disease fatal (Sabayan, 
Jansen, et al., 2012). 
There is a strong correlation between AD and poor Cerebral Blood Flow (CBF) (Sun, Zhu, et al., 2007). 
Cognitive decline occurs naturally with age; however, a more severe decline, as in Mild Cognitive 
Impairment (MCI), is a precursor to AD. Observational studies have shown that the treatment of 
vascular risk factors including hypertension, diabetes, cerebrovascular diseases, and 
hypercholesterolemia, decrease the risk of dementia progression (Li, Wang, et al., 2011; Daulatzai, 
2017). 
Currently, FDA has not cleared or approved any medical devices for the treatment of AD or MCI. Non-
pharmacological strategies for delaying the progression of cognitive deficits and resulting functional 
impairment in AD, have produced limited results and only include activities such as art therapy, activity-
based therapy and memory training. Given the lack of a highly effective and safe treatment for AD, there 
is a strong unmet medical need for additional treatment options. 
Evidence suggests that there may be a significant cerebral vascular component to cognitive impairment 
associated with AD and therefore, treatments targeting cerebral perfusion and vascular health are 
worth pursuing (Paillard, 2015). External counterpulsation (ECP) treatment improves coronary and 
peripheral vascular health and may improve cerebral vascular health. Physical exercise is the most basic 
and efficient way to improve blood flow (Erickson, Voss, et al., 2011) and has been shown to increase 
cardiac output, which in turn leads to an increase in CBF (Paillard, 2015). Wang, Karp, et al. (2002) and 
Verghese, Lipton, et al. (2003) have shown that elderly patients who partake in physical activity are less 
likely to develop dementia and experience cognitive decline. However, due to cognitive or physical 
decline, patients with signs of dementia are not always able to exercise. RenewTM NCP-5 is designed to 
simulate the effects of sustained vigorous exercise, which otherwise may not be feasible for patients 
with MCI/AD. 
RenewTM NCP-5, an External Counterpulsation (ECP) device, has a well-established safety profile and 
may increase cerebral perfusion that could be beneficial in the treatment of MCI due to AD and mild 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 9 of 78dementia of the Alzheimer's type (mild AD). Therefore, Renew Research, LLC, the sponsor, plans to 
conduct a clinical trial to establish safety and effectiveness for the proposed indications. 
1.2  RenewTM NCP-5
RenewTM NCP-5, an ECP device, is a non-invasive treatment that improves coronary and peripheral 
vascular health and may improve cerebral vascular health. It enhances circulation and stimulates 
endothelial production of trophic factors such as nitric oxide, resulting in peripheral vasodilation, 
reduction in vascular inflammation and improved vascular compliance. These and other factors result in 
increased coronary artery blood flow, reduced cardiac afterload and reduced systemic blood pressure. 
Thus, RenewTM NCP-5 has been used to treat patients with chronic angina and Congestive Heart Failure 
(CHF) by increasing cardiac output and reducing the workload of the heart. ECP increases cardiac output 
by improving systolic unloading and venous return (Barsness, 2001). Patients with CHF have an 
increased risk of cognitive dysfunction presumably because of decreased CBF. In a study done by 
Kozdag, Iseri, et al. (2013), ECP therapy resulted in improvement in all cognitive domains except visual 
and verbal memory tests in patients with CHF. Thus, RenewTM NCP-5 may be used as an exercise 
alternative to increase CBF. The effects of RenewTM NCP-5 may act similarly to exercise therapy and are 
explored for patients with mild AD and MCI in this study. 
Counterpulsation is a term that describes balloon inflation, when internal, or synchronized pressure 
during diastole and deflation in early systole, when external. During the RenewTM NCP-5 session, the 
patient’s lower extremities are wrapped in three compressive pneumatic cuffs applied to the calves, 
lower thighs, and buttocks. Electrocardiogram (ECG)-gated, sequential leg compression occurs as these 
cuffs are inflated from distal to proximal in early diastole and then rapidly deflated at the onset of 
systole. The rapid inflation increases diastolic pressure (diastolic augmentation), increasing coronary 
perfusion pressure and myocardial perfusion. The rapid cuff deflation promotes lower extremity arterial 
“runoff” and leads to a decrease in systolic pressure (systolic unloading), thereby reducing cardiac 
afterload. The RenewTM NCP-5 session also increases venous return, promoting an increase in cardiac 
output. 
The pressure causes 'volume displacement' of blood within the aorta, both proximally and distally. This 
leads to a potential increase in coronary blood flow and potential improvements in systemic perfusion 
by augmentation of the intrinsic 'Windkessel effect' (Catanho, Sinha, & Vijayan, 2012) whereby potential 
energy stored in the aortic root during systole is converted to kinetic energy with the elastic recoil of the 
aortic root (Belz, 1995). This effect produces diastolic augmentation by forcing freshly oxygenated blood 
back toward the heart and coronary arteries at the beginning of diastole. Additionally, the volume of 
venous blood returned to the heart under pressure increases both oxygen supply and perfusion 
pressure in the myocardium. This effect increases heart preload (giving the heart greater volume to 
pump) and reduces heart afterload as the vascular beds in the lower extremities are emptied by the 
pressure. Thus, work and oxygen demand on the heart muscle is decreased. As a result, the patient's 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 10 of 78peak diastolic pressure is significantly increased, benefiting the heart muscle and other organs, such as 
the kidneys, due to increased circulation. At the same time, the patient's systolic pressure is also 
reduced to the general benefit of the vascular system (Campbell, Satran, et al., 2008). This effect has 
been shown to produce measurable and reproducible beneficial cardiovascular effects in healthy 
individuals (Hilz, Werner, et al., 2004) as well as individuals with cardiac compromise such as angina, 
heart failure or coronary artery disease (Shechter, Matetzky, et al., 2003; Braith, Conti, et al., 2010). 
1.3 Mechanism of Action
The physiologic effect of RenewTM NCP-5 is comparable to mild/moderate exercise, which is beneficial in 
normal and sick persons. Both exercise and ECP improve endothelial function, and account for the 
action of ECP (Gurovich & Braith, 2013; Bonetti, Barsness, et al., 2003). The results of the hemodynamic 
effects are proliferation of collateral circulation in the heart, vasodilatation due to enhanced endothelial 
functioning, and peripheral conditioning. All these effects produce clinical benefits including 
improvements in the cardiovascular system and other organs. 
Low shear stress, the frictional force per area that is exerted by blood flow on the vessel wall, is found in 
MCI and AD (van Es, van der Flier, et al., 2009). A key physiological outcome that connects proliferation 
of collateral arteries to endothelial function is the increase in shear stress resulting from the increase in 
flow velocity due to the diastolic augmentation created by ECP (Zhang, He, et al., 2007). First, the action 
of the sequential (legs to thighs to buttocks) compression at the onset of diastole pushes blood from the 
peripheral vessels up to the heart. This action is known as diastolic augmentation. As the heart enters 
systole, the pressure is released, thereby decreasing the work of the heart resulting in decreased oxygen 
consumption, adaptive proliferation of coronary collateral arteries (arteriogenesis), and improved 
cardiovascular functioning (Buschmann, Utz, et al, 2009; Pagonas, 2011). Additional coronary effects 
include improved endothelial function and decreased peripheral resistance due to increased shear stress 
as flow velocity increases, which activates the nitric oxide cycle and produces vasodilatation (Bonetti, 
Barsness, et al., 2003; Jerca, Jerca, et al., 2002; Michel & Feron, 1997). This phenomenon has also been 
referred to as a decrease in arterial stiffness (increase in elasticity) (Hui, Lawson & Barness, 2010; Casey, 
Beck, et al., 2011). The increase in elasticity promotes the Windkessel function within the aorta as it 
serves as a buffering chamber behind the heart to forward blood from the left ventricle into the 
peripheral circulation (Belz, 1995). It was demonstrated that shear stress can promote improved 
endothelial functioning by stimulating growth factors and activating the nitric oxide cycle and 
endothelin-1 cycle (Papaioannou & Stefanadis, 2005), which results in vasodilatation. In addition to 
these improvements in coronary function and the cardiovascular system, there is the effect of passive 
exercise leading to conditioning of the peripheral vasculature. This is accomplished through sequential 
compression on the lower extremities that leads to increased blood flow in a similar manner to physical 
activity.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 11 of 781.4 Implications for Cerebral Blood Flow
Age related neurodegenerative and vascular associated pathologies exist in patients with MCI and AD. 
Increased atherosclerosis/arteriosclerosis of the intracranial arteries are found in AD leading to ischemia 
and cognitive dysfunction. Studies indicate that pulse pressure (systolic blood pressure-diastolic blood 
pressure) reflects the elasticity of large arteries and is an increased risk for dementia (Peters, Beckett, et 
al., 2013). One study confirmed that CBF 20% lower in AD than age-matched normal was correlated with 
decrease pulse pressure and compromised cognitive performance. CVD and brain hypoperfusion may 
participate in the pathogenesis of neurodegenerative disease (Rohrer, Debbins, et al., 2012). 
Studies have shown a positive effect on CBF from ECP with a subsequent change in cognitive scores. ECP 
has undergone a preliminary investigation in patients with senile dementia of the Alzheimer type. Li, 
Yao, et al. (1994) treated 10 patients (mean age 74.5 years) with ECP for one hour a day for a total of 48 
hours in eight weeks and all 10 patients completed the ECP treatments with no adverse events. 
Following ECP treatment, patients showed a mean increase in their Hasegawa’s Dementia Scale score of 
1.9, although the mean change was not statistically significant. In addition, pre- and post-treatment 
SPECT scans were completed in six of the 10 patients. The SPECT scan results demonstrated that cortical 
perfusion was significantly increased post-ECP compared to pre-ECP. 
Moriarty, Badawi, et al. (2016) studied ECP treatment in four MCI patients. All four patients completed 
35 one- hour treatments over seven weeks. CBF was assessed at baseline and post-ECP treatment by 
arterial spin labeling perfusion MRI. At baseline, blood flow in MCI patients was significantly less 
compared to healthy controls in the hippocampus (p=0.007) and inferior parietal lobe (p=0.013). While 
suggestive, perfusion increases were observed in the MCI patients post-ECP but did not reach 
significance in the hippocampus (p = 0.064) and precuneus (p = 0.057) in this small study of four 
patients. 
Acute ECP effects on CBF have not been studied in AD patients, but a number of studies have examined 
the effects in both healthy subjects and stroke patients. Studies have shown different effects in healthy 
subjects versus stroke patients. Researchers have hypothesized that healthy subjects exhibit cerebral 
autoregulation that is observed as an augmented diastolic CBFV during ECP, balanced by a 
corresponding drop in systolic CBFV for a net zero or small negative change in mean CBFV (measured in 
the middle cerebral artery) (Folstein, Folstein & McHugh, 1975, Marthol et al 2005, Jungehuelsing et al, 
2010). Since acute ECP studies have not yet been conducted for MCI or AD patients, it is unknown if 
augmented mean CBFV will be observed in addition to augmented diastolic CBFV. ECP could affect 
cerebral vascular health and cognition through indirect effects on the cardiovascular system or through 
acute effects on CBF (diastolic augmentation or mean CBFV). 
In summary, ECP has been shown to produce significant positive health benefits and the potential for 
enhanced coronary functioning in chronic stable angina, among other conditions. The same mechanisms 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 12 of 78by which ECP provides benefit in angina may also extend to brain perfusion. These benefits of ECP occur 
by similar mechanisms to vigorous exercise, as demonstrated in multiple published studies.  
2.DETERMINATION OF ELIGIBILITY 
This research study will test the safety and efficacy of the Renew ™ NCP-5 System (RenewTM NCP-5) for 
the treatment of Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the 
Alzheimer’s Type. Specifically, this study will evaluate how the Renew ™ NCP-5 device works in relation 
to changes in cognition. 
For any clinical study, it is important to ensure the eligibility of participating subjects and to understand 
the diversity of that population. Thus, similar studies of MCI and AD have used the Mini- Mental State 
Examination 2 (MMSE2), the Logical Memory Sub-Scale II of the Wechsler Memory test (LMII), and the 
Montreal Cognitive Assessment (MOCA) to assess cognition and the Cardiovascular Risk (CVR) scale to 
assess appropriateness to participate in a study.  
The MMSE2 is a brief assessment instrument used to assess cognitive function in geriatric patients. The 
MMSE2 can be used to screen for cognitive impairment and as a measurement of cognitive change over 
time. The instrument is divided into two sections. The first section measures orientation, and attention, 
while the second section tests the ability of the patient to name objects, follow verbal and written 
commands, write a sentence, and copy figures. Folstein, Folstein, et al. (1975) demonstrated the MMSE2 
to be both reliable and valid in a group of elderly subjects: including those with dementia, depression 
with cognitive impairment, depression and "normal" elderly patients. The validity of the MMSE2 is 
demonstrated by a positive correlation between the patients' MMSE2 scores and their scores on both 
the verbal and performance sections of the Wechsler Adult Intelligence Scale. The MMSE2 has been 
shown to possess sensitivity and specificity in various populations. Although the MMSE2 alone is unable 
to provide diagnostic information, the data on its sensitivity and specificity in cognitively impaired 
patients demonstrates its utility as a screening instrument. The Logical Memory Sub-test of the Wechsler 
Memory Scale is a standardized assessment of narrative episodic memory, assessing immediate recall 
and delayed recall.  
The MOCA is a widely used cognitive assessment for patients with Mild Cognitive Impairment due to 
Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type. It includes a memory recall test, 
visuospatial abilities, executive function, attention, concentration, working memory, naming and 
orientation to time and place. Subjects with a MOCA score of greater than or equal to 11 will be 
included in the study. In a validation study by the developer of the MOCA (Nasreddine, Z Phillips, NA 
2005), 94 patients diagnosed with MCI and 93 patients diagnosed with mild AD were assessed by the 
MMSE2 and MOCA. The MOCA was significantly more sensitive in detecting MCI (90%) vs MMSE2 
(18%). Further, the MOCA detected mild AD more reliably (100%) than the MMSE2 (78%). These 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 13 of 78findings were confirmed by other investigators (Luis CA, Keegan AP, Mullan M, 2009). MOCA has been 
used extensively in studies of MCI and mild AD. (Ciesielska N, Sokolowski R, Mazur E, et al 2016).  
The study checklists were developed based on the following 2011 National Institute on Aging (NIA) -
Alzheimer’s Association (AA) “core clinical criteria” guidelines: (i) The diagnosis of dementia due to 
Alzheimer’s disease & (ii) The diagnosis of mild cognitive impairment due to Alzheimer’s disease, which 
will be used in conjunction with the MMSE2, LM, and MOCA tests. All required checkboxes within the 
study checklist for “The diagnosis of probable AD dementia” must be “yes” to qualify for inclusion into 
the study as a subject with mild AD. If the patient does not meet all the required criteria in the study 
checklist for “The diagnosis of probable AD dementia,” the site will proceed with completing the study 
checklist for “The diagnosis of mild cognitive impairment due to Alzheimer’s disease,” and all required 
checkboxes must be “yes” to qualify for inclusion into the study as a subject with MCI due to AD. 
Understanding the importance of vascular status, the Cardiovascular Risk Assessment (CVR) will be used 
to assess the subject’s cardiovascular risk. The CVR score will be calculated based on the 2013 ACC/AHA 
Guideline on the Assessment of Cardiovascular Risk, which will be used to stratify subjects at baseline 
into a 10-year low/medium risk vs. high/very high risk, based on CVR score (Goff, Lloyd-Jones, et al., 
2013). 
2.1 Assessment of Cognition
The objective of the study is to determine the efficacy of Renew ™ NCP-5 System for the treatment of 
Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type as 
measured by changes in cognition. Thus, various assessments of cognition used in similar studies will be 
implemented. 
The vADAS-Cog (Vascular Dementia Assessment Scale) is an expanded version of the Alzheimer’s Disease 
Assessment Scale (ADAS-Cog14), that is being used in the National Institute on Aging Alzheimer’s 
Disease Research Centers (National Institute on Aging, 2018). The ADAS-Cog is an instrument devised to 
assess the severity of cognitive impairment in patients with AD. The scale includes short 
neuropsychological tests in which the patient performs simple tasks such as word recall, word 
recognition, and constructional praxis. The cognitive section of the ADAS-Cog consists of two items that 
assess the following: language (aphasia) and motor skills (praxis ). Rosen, Mohs, et al. (1984) evaluated 
the test-retest and interrater reliabilities of the individual scale items and the entire scale in patients 
with dementia of the Alzheimer's type. The ADAS-Cog was shown to be valid in the ability to detect 
patients with clinically diagnosed AD from matched non-demented controls. Kramer-Ginzberg, Mohs, et 
al. (1988) demonstrated at I2 month and 24 month retesting that higher scores on the ADAS-Cog 
correlated with disease progression. Because both of the above cognitive and non-cognitive parameters 
are assessed, the ADAS-Cog is a reliable instrument for use in psychopharmacologic trials involving 
patients with AD.
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 14 of 78The vADAS-Cog has been shown to be a more sensitive measure of cognition than ADAS-Cog in subjects 
with vascular burden in the brain (Ylikoski, Jokinen, et al., 2007). The vADAS-Cog is made up of ADAS-
Cog14 plus three additional tests: the symbol digit test (the number of correct responses in 90 s); the 
digit span backward test (the number of digits recalled backwards); and the verbal fluency test (animal 
category in one minute). 
Additional neuropsychological assessments used in other studies show changes over time and assess the 
importance of change to the clinician and caregiver (ADCS-CGIC) and the ability of the subject to carry 
out activities of daily living (ADCS-ADL). The Trail Making Test B is used in many studies to assess 
executive function, a key to continued functioning for the patient.  
2.2 Imaging and Physiological Assessment 
2.2.1 Imaging Studies 
Imaging studies may be important in understanding the mechanism by which treatment results in 
change in cognition or delays the progression of the disease. Both structural/clinical imaging and 
functional/vascular physiology will be assessed.  
Changes in hippocampal volume over time, measured by MRI, have been extensively used as a 
biomarker for MCI and AD. The European Medicines Agency (EMA) has qualified hippocampal volume as 
a biomarker for selecting patients for trials in early AD (Hill et al, 2014). FDA has cleared software for 
MRIs to measure hippocampal volume (Ahdidan et al, 2016).  
A vascular component is seen in the great majority of cases of MCI and mild AD (Snyder et al, 2015, Di 
Marco et al, 2015, Strickland, 2018). Assessing changes in cerebral blood flow can inform the mechanism 
of change in the vascular contribution to MCI and AD (Bron et all, 2014). It should be noted that no 
known AD biomarkers have yet been qualified by the Food and Drug Administration (FDA) as a valid 
surrogate marker of clinical decline that can be used as a substitute for clinical measures. 
2.2.2 Hippocampal Volume as a Biomarker of Disease Modification 
Hippocampal volume is one of the best-established biomarkers used in research to stage the 
progression of AD (Trzepacz et al, 2016). The hippocampus is a key structure in mediating memory 
processes (Pohlack et al, 2014, Hebscher et al, 2017, Longoni et al, 2015) and is affected early in AD 
(Vecchio et al, 2017, Zhao et al, 2017). Hippocampal volume correlates with AD neuropathological 
burden, particularly neurofibrillary tangles (Thaker et al, 2017). Hippocampal volume changes are widely 
used as clinical trial endpoints to provide evidence in support of disease modification (Bredesen et al 
2016, Pini et al, 2016). A recent meta-analysis found hippocampal atrophy in AD to be 4.66% (3.92-5.4), 
significantly higher than the 1.41% (0.52-2.30) in older normal adults (Barnes et al, 2009). Additionally, 
Schuff et al (Schuff et al, 2009) evaluated 112 cognitive normal elderly individuals, 226 MCI and 96 AD 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 15 of 78patients, and found that MCI and AD patients showed significantly more hippocampal volume loss over 
six months and accelerated loss over 12 months. Therefore, a reduction in hippocampal atrophy 
compared to placebo could support disease-modification if corresponding clinical benefit is also 
observed. These factors have led to widespread efforts to utilize hippocampal volume as a surrogate 
marker of AD, including as noted above, by the EMA. 
2.2.3 Regional Cerebral Blood Flow and White Matter Hyperintensities as Potential Biomarkers of 
Disease
Blood flow is reduced in AD and is known to lead to brain tissue damage, which in turn accelerates the 
course of the disease. Vascular risk/disease is highly comorbid with AD (Gottesman et al, 2017, 
Rabinovici et al, 2017) and is linked to conversion from cognitively healthy to MCI (Bangen, Preis, et al., 
2018), with increased risk for an AD diagnosis (Arvanitakis, Capuano, et al., 2016; Brickman, Zahodne, et 
al., 2015). Decreased blood flow thus influences the clinical progression of the disease (Bhargava, 
Weiner, et al., 2006). In fact, it has been suggested that a ‘two hit’ process of vascular and classical AD 
pathology is necessary for the full expression of AD dementia (Nelson, Sweeney, et al., 2016).  
Vascular disease can be expressed in many forms. In the brain, cerebral blood flow is reduced in AD and 
MCI (Alsop, Detre, et al., 2000; Dai, Lopez, et al., 2009), and has been shown to be associated with 
neurovascular dysfunction that affects the brain’s ability to auto-regulate blood flow (Kisler et al, 2017). 
Reductions in CBF are linked to more rapid conversion from MCI to AD (Hirao, Ohnishi, et al, 2005;) and 
regional CBF tracks with cognitive symptoms in patients with AD. Alterations in CBF are strong in regions 
known to exhibit early and high classical AD pathology (Dai, Lopez, et al., 2009; Hirao, Ohnisi, et al., 
2009). Reduced CBF is also found in individuals who are not impaired but are at risk for AD, for example 
in carriers of the APOE4 gene allele (Van der Lee, et al, 2018). The utility of CBF as a biomarker for early 
AD has been justified (Hays, Zlatar, & Wierenga, 2016). Specifically, as a biomarker, CBF has diagnostic 
utility for prediction of individuals with MCI that will progress and/or convert to AD as well as in tracking 
progression of AD. In this regard, CBF is considered a mechanism of disease that should be targeted 
through novel therapeutics and may provide an important indicator of disease modification for slowing 
the progression of AD. 
Regional CBF can be assessed and quantified by MRI (Zhang et al, 2017). High quality anatomic images 
demonstrated decreased flow in the temporal, parietal, frontal, posterior and cingulate cortices. Severe 
cognitive dysfunction as measured by MMSE2 correlated with decreased CBF in the post parietal and 
post cingulate cortices. In another study (Roher, Debbins, et al., 2012), age related neurodegeneration 
and vascular associated pathologies, such as arteriosclerosis, may increase brain hypoperfusion and lead 
to increased risk of AD.  
A second way that vascular disease is expressed in the brain is through secondary vascular-associated 
brain tissue damage. Vascular disease can be expressed in many forms. In the brain, white matter hyper 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 16 of 78intensities (WMH) of presumed vascular origin (Wardlaw, Valdes Hernandez & Munoz-Maniega, 2015) 
seen on magnetic resonance imaging (MRI) are in part due to cerebral hypoperfusion (reduced cerebral 
blood flow) resulting in hypoxic, ischemic tissue damage to the white matter connections in the brain 
(Fernando, Simpson, et al., 2006; Black, Gao & Bilbao, 2009). WMH are therefore related to alterations 
in brain function and cognition generally and not specific to AD. However, WMH are much more highly 
prevalent in AD compared to cognitively healthy older adults (Coutu, Goldblattt, et al., 2016) and may be 
more predictive of decline than traditional imaging markers of AD pathology (Coutu, Lindemer, et al., 
2017). Enhancement of vascular processes that increase CBF and reduce WMH burden therefore may 
represent an important disease-modifying target for dementia.  
Similar to primary affected structures such as the hippocampus which are affected long before a 
diagnosis of AD, the rate of WMH increase also accelerates several years before a diagnosis of MCI 
(Silbert, Dodge, et al., 2012). Dynamic tissue changes within WMH occur just prior to the conversion 
from MCI to AD (Lindemer, Salat, et al., 2015), suggesting that prevention of such damage may slow the 
conversion from an independent to dependent clinical state. Additionally, WMH are highly correlated 
with primary imaging markers of AD pathology such as hippocampal and ventricular volumes (Coutu, 
Goldblatt, et al., 2016), suggesting that vascular disease may exacerbate the primary pathology of AD. 
The annual increase in WMH volume is reported to be between 12.5% and 25% in community dwelling 
individuals with early confluent lesions or greater at baseline (Schmidt, Enzinger, et al., 2003). WMH 
have been explored as surrogate clinical trial endpoints for small vessel disease (Schmidt, Scheltens, et 
al., 2004). A therapeutic increase or preservation in CBF and/or a decrease or preservation of WMH 
volume could support disease-modification. This hypothesis would be strengthened if corresponding 
clinical benefits were also observed. 
2.2.4 Physiological Assessments 
Falls in older people with dementia or cognitive impairments increases rates of hospitalization, 
dependence, depression and caregiver burden.  
The Timed Up & Go Test is a common clinical screening tool used to assess a patient’s mobility, balance, 
gait speed, and fall risk. The patient is timed while they rise from an arm chair, walk to a line on the floor 
three meters away, turn around and walk back to the chair and sit down again. The subject wears his 
regular footwear and uses his customary walking aid (cane or walker) if necessary (Barry, Galvin, et al., 
2014). 
The Functional Reach Test is a valid and reliable measure used to identify deficits in dynamic balance 
and fall risk. It is a single-task, dynamic measure of the difference in arm’s length and maximal forward 
reach using a fixed base of support in the standing position (Duncan, Weiner, et al., 1990).
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 17 of 782.3 Blood studies
Exploring the changes in blood factors in MCI and AD patients may lead to a better understanding of 
how they may contribute to the development of dementia.  
Alterations in quantity and quality of blood cells may be involved in the pathogenesis of AD and may 
contribute to disease progression (Turcato, Serafini, et al., 2016). In a recent study (Chen, Bu, et al., 
2017), AD patients were found to have increased levels of mean corpuscular hemoglobin, mean 
corpuscular volume, red cell distribution width-standard deviation, mean platelet volume and decreased 
levels of platelet distribution width, red blood cell, hematocrit, hemoglobin, lymphocyte, and basophil 
compared to normal controls. 
Serum markers of hypercoagulability and markers of inflammation lead to thrombosis, accelerated 
atherogenesis and dementia (Gupta, Watkins & Thomas, 2005). A 2009 study (Smith, Chen, et al., 2009) 
suggests that vessel diameter, flow velocity, and whole blood viscosity are altered in AD subjects 
compared to controls. AD patients had significantly increased whole blood viscosity, which was 
correlated with disease severity (Smith, Chen, et al., 2009). In another study (Chang, Liang, et al., 2007), 
fibrinogen concentration and mean corpuscular cell volume levels of erythrocytes were significantly 
higher in AD patients. 
Oxidative stress-induced elevation of fibrinogen concentration could lead to accelerated erythrocyte 
aggregation as a result of blood viscosity and blood viscoelasticity leading to impaired oxygen transport 
efficiency in the blood of AD patients. 
Inflammatory markers such as C-reactive protein and Lp-PLA2 and MPO are implicated in the 
pathogenesis of AD and VD. C-reactive protein (CRP) is a strong marker of VD in early stages of the 
disease (Androsova, Mikhailova, et al., 2013). 
Lipid levels may be related to development of MCI and AD and significantly lower lipid levels have been 
found in patients with AD than controls. Late phases of AD show significantly lower entire lipid profile 
and significantly lower cholesterol and LDL-C. Lipid profile may be connected to the etiology and 
progression of AD. An association between low serum cholesterol and LDL-C levels and cognitive decline 
in AD have been shown (Persecki, Muck-Seler, et al., 2011). 
3.RATIONALE 
Understanding the impact of RenewTM NCP-5 on increasing cardiac perfusion and its similarity to 
exercise in increasing blood flow to not only the heart but to other organs in the body, this study 
assumes that the RenewTM NCP-5 will increase cerebral blood flow. Renew Research, LLC anticipates 
that RenewTM NCP-5 session intervention may effectively treat or delay cognitive impairment from Mild 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 18 of 78Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type. Studies 
show that ECP improves cardiac output and arterial stiffness, and may have the potential to improve 
cerebral blood flow. These effects could have a positive effect on cognitive impairment. Please see 
Figure 1 below. 
Figure 1 .
Figure 1: A model for cognitive impairment, cerebral vascular health, and potential points at which RenewTM NCP-5 
could play a positive role.
3.1 Potential Risks
In accordance with 21 C.F.R. Part 812 and FDA’s guidance document entitled “Significant Risk and 
Nonsignificant Risk Medical Device Studies” (Jan. 2006), FDA concurred with Renew Research LLC’s 
conclusion that its proposed clinical study poses nonsignificant risk (NSR) and therefore is subject to the 
abbreviated IDE requirements found in 21 C.F.R. 812.2(b). The Renew ™ NCP-5 System does not qualify 
as significant risk for purposes of an IDE because: (1) the device is not an implant; (2) the device is 
proposed to be used as a treatment for MCI and mild AD, and is not intended for a use in supporting or 
sustaining human life; and (3) while the device is of substantial importance in diagnosing, curing, 

Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 19 of 78mitigating, or treating disease, including mild AD, or otherwise preventing impairment of human health, 
(4) the device does not present a potential for serious risk to the health, safety, or welfare of a subject. 
RenewTM NCP-5 therapy is safe in healthy patients, as well as in patients with atherosclerosis, coronary 
artery disease, cerebrovascular diseases and other comorbidities that may exist in the AD population. 
Only minor adverse events have been recorded during treatment with RenewTM NCP-5. Moreover, 
RenewTM NCP-5 has been used in patients who suffered from ischemic stroke, including in cases where 
the drug dextran was being used (Han & Wong, 2008), and subjects suffering from AD (Li, Yao, et al., 
1994) without serious complications. Lastly, RenewTM NCP-5 has previously been used in older patient 
populations in multiple studies (e.g., average age: 63 years (Applebaum, Kasliwal, et al., 1997), 64 years 
(Werner, Marthol, et al., 2003), and 74.5 years (Han & Wong, 2008)) without complications. 
AD presents as neurological degeneration that disrupts neuron-to-neuron communication and leads to 
cell death. Neurological degeneration and cell death, however, will not place AD patients at a greater 
risk than other populations undergoing RenewTM NCP-5 treatment. While patients with AD often have 
several comorbidities, primarily due to the more advanced age of the AD population, the study 
screening process will effectively exclude conditions that may place a subject at a higher risk during 
RenewTM NCP-5 treatment. This will include subjects with congestive heart failure, deep vein 
thrombosis, elevated heart rate, heart valve disease, and untreated high blood pressure, among others. 
Study subjects with these conditions, who are at a greater risk during RenewTM NCP-5 treatment, will be 
excluded from the study. Moreover, study subjects will not need to terminate their current treatment 
regimen in order to participate in the study, except under limited circumstances. Subjects will thus not 
be subject to heightened risk that may be associated with the termination of their current treatment 
regimen. 
The conclusion that treatment with the RenewTM NCP-5 External Counterpulsation System does not 
present a serious risk to health is supported by the academic literature and historical safe use of 
RenewTM NCP-5 therapy. The physical symptoms of mild AD, neurological degeneration and cell death, 
will not place subjects at a heightened risk. In addition, comorbidities found in the AD population that 
would subject a patient to heightened risk during RenewTM NCP-5 will be excluded during the screening 
process. Given that RenewTM NCP-5 has been used in medical treatment for over 50 years, the 
conditions that heighten patient risk during RenewTM NCP-5 treatment are well established and are 
reflected in the study protocol. Moreover, patients will be required to maintain their current treatment 
regimen during participation in the proposed study. 
Specifically, minor adverse events reported from the use of the RenewTM NCP-5 External 
Counterpulsation System and approaches to mitigating the risks are as follows: 
Skin irritation, abrasions, bruising and breakdown around the areas on which the device is 
placed has been reported but are transient. Fabric sleeves can be used under the 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 20 of 78compression cuffs to minimize the chance of skin irritation. Subjects can also use topical 
creams after treatments to reduce irritation. 
Mild headaches and musculoskeletal pain, including leg and low back pain have been 
reported. Patients with a history of either of these chronic problems may be excluded from 
study participation or withdrawn from treatment if symptoms become unmanageable. The 
use of over the counter analgesics will help alleviate the discomfort. 
Edema in the legs may occur but is generally transient. If it persists, support hose can be 
used between treatments.  
Toothache is generally transient and can be treated with over the counter analgesics. 
Fatigue 
There are potential risks from other assessments that will be performed: 
Some subjects may experience anxiety or feelings of claustrophobia from the MRI. Study staff 
will explain the MRI procedure and answer any questions. Earplugs/headphones will be given to 
the participant to decrease the noise associated with the MRI. If necessary, an anxiolytic may 
also be prescribed. Study staff will explain that there will be no exposure to radiation and will 
exclude anyone who has metallic parts in their bodies. 
When blood is drawn, the participant may feel discomfort or experience some bruising, both of 
which are transient. Skilled phlebotomists will explain the procedure and ensure there is 
minimal trauma and anxiety. 
There are no reported risks associated with performing ultrasound Doppler. Patient anxiety with 
these assessments will be addressed by the study staff and operator. 
3.2 Potential Benefits
The clinical research study team cannot and does not guarantee or promise that subjects will receive 
any benefits from this study. However, it is anticipated that treatment with RenewTM NCP-5 will improve 
cognition and may slow the progression of MCI or AD. At the very least, subjects will have access to this 
device, RenewTM NCP-5, which would otherwise not be available to them. 
4.STUDY OBJECTIVES AND PURPOSE 
The purpose of the study is to identify a safe and effective approach to treatment for Mild Cognitive 
Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type as measured by 
changes in cognition and identify a biomarker to measure disease progression.  
The primary objective of the study is to determine the efficacy of RenewTM NCP-5 treatment for Mild 
Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type as measured 
by changes in cognition.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 21 of 78The secondary objectives of this study are to: 
Evaluate the safety of RenewTM NCP-5 therapy in treatment for MCI due to AD and mild 
dementia of the Alzheimer’s type.  
Confirm the effectiveness of RenewTM NCP-5 treatment through additional neuropsychological 
testing. 
In addition, exploratory objectives of this study are to: 
Evaluate the physiological mechanism of action of RenewTM NCP-5 treatment related to 
cognition as measured by cognitive and neuro-behavioral assessments, biological markers, 
ultrasound and laboratory assessments.
Understand the relationship of hippocampal volume change over time to changes in cognition. 
Compare ADAS-Cog12 scores at 12, 24, 36, and 48 weeks between an external control arm of 
digital twins and each of the actual treatment and active sham groups.  
5.STUDY DESIGN AND ENDPOINTS 
5.1 Study Design
This pivotal, single blind, parallel design, multi-site study intends to examine the efficacy and safety of 
RenewTM NCP-5 therapy in the treatment of Cognitive Impairment due to Alzheimer’s Disease or Mild 
Dementia of the Alzheimer’s Type. Subjects will be prospectively randomized to treatment or active 
sham (in a 1:1 ratio) using stratification for Cognitive Impairment due to Alzheimer’s Disease or Mild 
Dementia of the Alzheimer’s Type, and CVR score at multiple sites. Subjects will be assessed for 
stratification and then randomized within strata to either the treatment group or active sham group 
with one treated subject for one active sham subject. Randomization assignments will be made using 
permuted blocks. Investigators shall receive the assignments from an Interactive Web Response System 
(IWRS). The following factors will be used for stratification prior to randomization: cognitive decline 
(MCI due to AD vs. mild AD) and CVR score (low/medium vs. high/very high). 
Additional pre-specified subgroup analyses of the primary efficacy outcome will be conducted using the 
same method as the primary analysis. The subgroup includes cognitive decline (MCI due to AD vs. mild 
AD) and CVR score (low/medium vs. high/very high). These subgroup analyses results will not be used to 
draw conclusions of efficacy. The subgroup analyses will serve as a supportive purpose to the primary 
analysis; therefore, Type I error will not be adjusted for the subgroup analyses.  
Prior to randomization, subjects will be diagnosed with either Cognitive Impairment due to Alzheimer’s 
Disease or Mild Dementia of the Alzheimer’s Type, based on the study checklist developed, which 
follows the 2011 National Institute on Aging (NIA)-Alzheimer’s Association (AA) “core clinical criteria” 
guidelines. After the subject completes the MMSE2, LMII and the MOCA, the investigator will review the 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 22 of 78results and complete the 2011 NIA-AA study checklist, which identifies the “core clinical criteria” for 
diagnosis of probable AD dementia as indicated by the presence of cognitive and/or behavioral 
symptoms. Positive responses to the first five questions are required for inclusion in the mild AD cohort. 
If the responses to the first five questions within the checklist for the diagnosis of probable AD dementia 
are not positive, the investigator will then complete the 2011 NIA-AA “core clinical criteria” study 
checklist for MCI due to AD. Responses to the first four questions of that study checklist for the diagnosis 
of MCI due to AD must be positive, and the clinical impression must conform with typical presentation of 
individuals for whom there is an intermediate level of certainty that they have MCI due to AD, in order 
for subjects to be included in the MCI due to AD cohort.  
The MOCA, LM, MMSE2, and the complaint of memory loss by the subject and/or caregiver will be used 
to assess the subject; however, eligibility for the study will be determined by a MOCA score of greater 
than or equal to 11. The efficacy of RenewTM NCP-5 treatments to influence cognitive symptoms will be 
evaluated through performance on the vADAS-Cog compared to the active sham treatment group.  
Subjects, ages 55-85, will be consented for 13 months study participation, and will receive thirty-five 60-
minute RenewTM NCP-5 treatment sessions during a 7-to-12-week initial treatment period, and then 
transition to a lower frequency maintenance period (twice a week) for a total treatment period of 24 
weeks. During the initial treatment period (~1-12 weeks) subjects should be treated five days per week 
but at a minimum receive treatments three days per week.  For subjects who are unable to complete 5 
treatment days per week, the treatments should be spread-out as much as possible.  In order to 
complete 5 treatments per week, it is permissible for those subjects to have 2 treatments per day as 
long as there are no more than 3 days between treatments. If two treatments are conducted on the 
same day, subjects will need to wait a minimum of one-hour between treatments. Treatments should be 
completed per the above schedule. The schedule may be adjusted due to holidays or extenuating 
circumstances.  If subjects need to miss visits during any particular week, then treatments should be 
added to the week prior to or after the missed visits.  A total of 35 treatments must be completed within 
the 12-week period.  More than 7 days between treatments would be considered a protocol violation. 
Once the first 35 treatments have been administered, subjects will start the maintenance period. During 
the maintenance period, subjects should be treated two days per week, one session per day with a 
minimum of two full days between each treatment. Subjects may be rescheduled on an as needed basis 
as long as 6 treatments are maintained within a 3-week period. Rescheduling should be kept to a 
minimum and all efforts should be made to have treatments every week.
Assessment visits should occur the day following the last treatment session but no later than 2 days (48 
hours) after the last treatment. If necessary, on an as-needed basis, a treatment session of 30 minutes 
or more (≥ 30 minutes) will be considered as a completed session.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 23 of 78The investigator will assess vADAS-Cog at baseline, 6, 12, 18, 24 weeks, 9 and 12 months, or upon 
termination of treatment. Testing sessions will include additional secondary psychological assessments 
including the National Institute on Aging’s Alzheimer’s Disease Cooperative Study-Clinical Global 
Impression Scale (ADCS-CGIC) by the clinician and patient/caregiver and the Alzheimer’s Disease 
Cooperative Study-Activities of Daily Living (ADCS-ADL), Trail Making Test B, and ADAS-Cog. The ADCS-
ADL, ADCS-CGIC, Logical Memory and Trail Making will be completed by blinded psychometricians.  
Subjects will receive MRI brain scans at screening to ensure there is no existing exclusionary brain 
pathology. Brain pathology would include evidence of infection, infarction (including multiple lacunas in 
a critical memory structure), or other focal lesions. Central Reading of the MRIs will be conducted at 
Massachusetts General Hospital (MGH). Subjects who are re-screened for this study may utilize their 
initial screening MRI scan to determine eligibility if the initial screening MRI was completed within 90 
days of re-screening. At 24 weeks and end of study (12 month), an MRI will assess changes in 
hippocampal volume, a biologic marker for AD. A repeat scan may be obtained if necessary. Additionally, 
as exploratory endpoints, subjects treated at selected sites will receive Transcranial Doppler or the Moor 
deep tissue oxygenation to evaluate cerebral blood flow at study start and periodically throughout the 
trial period.  
Safety evaluation, including ongoing review of adverse events and vital signs will occur at every visit 
throughout the study. This trial will have frequent interim analyses to stop accrual early for expected 
success or for futility as outlined in more detail below. 
For exploratory endpoints, blood samples will be drawn at screening, 12 weeks, 24 weeks and 12 
months, or upon termination of treatment. A repeat lab draw may be obtained at any time if needed. 
Polymorphism of the apolipoprotein (ApoE) gene and its effect in modulating hippocampal change will 
be assessed at baseline. Additional exploratory lab endpoints include assessment of blood viscosity, 
inflammatory markers, and blood fibrinogen at baseline, 12 weeks, 24 weeks and 12 months, or upon 
termination of treatment. Exploratory endpoints of balance, functional mobility, and fall-risk will be 
measured via the Timed Up & Go (TUG) test and the Functional Reach Test at baseline, weeks 6, 12, 18, 
24, 9 and 12 months, or upon termination of treatment. Neuro-behavioral symptoms will be assessed 
using the Neuropsychiatric Inventory (NPI) at baseline, weeks 6, 12, 18, 24, 9 and 12 months, or upon 
termination of treatment. 
5.2 Endpoints
5.2.1 Primary Endpoint 
The primary endpoint for this study is the average of the change from baseline in vADAS-Cog score at 
12, 18 and 24 weeks after initiation of treatment . vADAS-Cog is an expanded version of the ADAS-Cog 
assessment, and the former has been shown to be a more sensitive measure of cognition than ADAS-
Cog in subjects with vascular burden in the brain.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 24 of 78The vADAS-Cog represents a collection of tests of different domains of brain function.  
A 2-point average change from baseline in vADAS-Cog at 12, 18 and 24 weeks after initiation of 
treatment will be used to determine effectiveness . Examples of the typical functional changes 
associated with a 2-point change in vADAS-Cog include: 
-Improvement in orientation – subject can now remember current date and day of week; 
-Less errors in naming – 50% reduction in mistakes naming a real object; 
-Improvement in following commands – subjects fail to follow 1/5 simple commands instead of 
3/5 commands previously failed; 
-Improvements in spoken language – misunderstanding decreases from moderately severe to 
mild (3-5 errors mean mild); 
-Better constructional praxis – 40% improvement in number of figures copied correctly; 
-Better word recall – 20% improvement in ability to remember words immediately after hearing 
them 3 times. 
It is expected that the effect of the treatment will be demonstrated first at 12 weeks but will maintain or 
improve through to 24 weeks of treatment. Accordingly, since the 12 week (the completion of initial 
phase of treatment), 18 week and 24 week (end of maintenance phase) vADAS-Cog scores represent the 
entire expected period of the treatment duration, it is appropriate to measure the average of 12, 18 and 
24 week vADAS-Cog scores as the primary endpoint for this study. The primary endpoint is the average 
of the change assessed at each of these three time points, referred to as an integrated primary 
endpoint. 
Sponsor will repeat the analysis of the primary endpoint using 9-month and 12-month data. 
As described in the Adaptive Design Report (ADR), included in Appendix A, the primary endpoint will be 
evaluated during interim analyses (after 100 subjects have been randomized and after every additional 
25 subjects are randomized), up to a total of 250 subjects. 
5.2.2 Secondary safety and effectiveness endpoints 
Because there is no gold standard to measure the changes from treatment in cognition for MCI or mild 
AD, secondary endpoints will include assessments performed in other similar studies. While cognitive 
and imaging assessments may show changes over time, it is important to assess the importance of 
change to the clinician and caregiver (ADCS-CGIC) and the ability of the subject to carry out activities of 
daily living (ADCS-ADL). The Trail Making Test B is used in many studies to assess executive function, a 
key to continued functioning for the patient. Because the vADAS-Cog includes the ADAS-Cog14 that has 
been used to assess changes in cognition in pharmaceutical studies, it is important to compare it to the 
findings from the vADAS-Cog. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 25 of 78The secondary effectiveness endpoints of the study include: 
The safety of RenewTM NCP-5 treatments as reflected in adverse events, labs and vital signs; 
The average of the change from baseline in Alzheimer’s Disease Cooperative Study-Activities of 
Daily Living ( ADCS-ADL ) Total Score at 12, 18 and 24 weeks after initiation of treatment; 
The answers to the NIA's Disease Cooperative Study-Clinical Global Impression of Change Scale 
(ADCS-CGIC ) at 12, 18 and 24 weeks after initiation of treatment;  
The average of the change from baseline in executive function, assessed by the Trail Making 
Test B  at 12, 18 and 24 weeks after initiation of treatment; 
The average of the change from baseline in ADAS-Cog14  at 12, 18 and 24 weeks after initiation 
of treatment. ADAS-Cog14 score will be calculated using the subtests from the vADAS-Cog test 
and will not be conducted as a separate test. 
Sponsor will repeat the analysis and conduct the battery of secondary endpoints on the 9 and 12 month 
data.  
5.2.3 Payor-based endpoints 
The payor-based endpoints, described below, will be used to assess the clinical and cost effectiveness of 
the RenewTM NCP-5 external counter-pulsation (ECP) for patients with Mild Cognitive Impairment due to 
Alzheimer’s Disease or Mild Dementia of the Alzheimer’s Type. Effectiveness of ECP on cognitive 
impairment, compared to active sham group, measured by the clinical effectiveness endpoints 
identified, will be key in communicating the value and benefits of adding ECP as a treatment option for 
this patient population. In order for physicians to widely access ECP as a treatment option for their 
patients, reimbursement from commercial payers will be required. To facilitate reimbursement, the 
study is measuring the impact of ECP on health related quality of life (HRQoL), reduction in disease 
burden,  and health resource ustilization (HRU) to help assess the cost effectiveness of ECP, and 
potential cost savings for health systems and payers. Results from this study will be presented to 
Centers for Medicare and Medicaid Services (CMS) and commercial insurers to initiate reimbursement 
approval of ECP. 
oA comparative analysis between treatment and active sham groups on  Health Resource 
Utilization (HRU) data  will be conducted using the following analysis and time points: 
The difference in change from baseline analyzed at: 
o24 weeks  
o9 months  
o12 months  
An average of 24 weeks, 9 months, and 12 months 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 26 of 78oA comparative analysis between treatment and active sham groups in their change of ability to 
drive based on a self-rated answer to a question 
oA comparative analysis between treatment and active sham groups in vADAS Cog Scores  will be 
conducted using the following analysis and time points:  
The difference in change from baseline analyzed at: 
o24 weeks,  
o9 months,  
o12 months; 
An average of 24 weeks, 9 months, and 12 months 
oA comparative analysis between treatment and active sham groups in ADCS-ADL Scores  will be 
conducted using the following analysis and time points: 
The difference in change from baseline analyzed at: 
o24 weeks  
o9 months  
o12 months  
An average of 24 weeks, 9 months, and 12 months 
oA comparative analysis between treatment and active sham groups in Fall Risk 
Assessment/Functional Reach Test/TUG Test Scores  will be conducted using the following 
analysis and time points: 
The difference in change from baseline analyzed at: 
o24 weeks  
o9 months  
o12 months  
An average of 24 weeks, 9 months, and 12 months 
oA comparative analysis between treatment and active sham groups in NPI Aggression Index 
Scores  will be conducted using the following analysis and time points: 
The difference in change from baseline analyzed at: 
o24 weeks  
o9 months  
o12 months  
An average of 24 weeks, 9 months, and 12 months 
oThe answers to the QOL/Patient Survey  at 12 months after initiation of treatment.  
5.2.4 Exploratory endpoints 
Imaging studies may be important in understanding the mechanism by which treatment results in 
change in cognition or delays the progression of the disease. Understanding that there is a vascular 
component to MCI and mild AD, assessing changes in cerebral blood flow can inform the mechanism of 
change. Research indicates that hippocampal volume change over time, measured by MRI, has potential 
as a marker for MCI and AD. MRI will be conducted at screening after all other assessments have found 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 27 of 78the subject to be eligible to participate in the study. This will allow results confirming no brain 
pathology, which would include evidence of infection, infarction (including multiple lacunas in a critical 
memory structure), or other focal lesions to be available for review at the baseline visit. If a history of 
cerebral aneurysm is suspected, the subject will be referred to their primary physician and/or 
neurologist.  
The exploratory endpoints for this study include:  
Evidence of altered peripheral or cerebrovascular physiology including: 
oThe observed value and change from baseline in hippocampal volume measured by MRI 
at 24 weeks and 12 months after initiation of treatment 
oChanges from baseline to 24 weeks after initiation of treatment or active sham in: 
Cerebral blood flow (CBF) in multiple regions (hippocampus, precuneus, 
parietal, inferior frontal lobe) measured by arterial spin labeling  between the 
treatment and active sham groups from screening, to 24 weeks and 12 months 
(selected sites only); 
Global cerebral blood flow as measured via MRI 
White matter hyperintensities as  measured via MRI
CBF velocity in cerebral arteries as measured by Transcranial Doppler at 
baseline, 12 and 24 weeks (selected sites only) 
Endothelial function via flow-mediated dilation (FMD) (brachial or femoral), as 
measured by ultrasound at baseline, 12 and 24 weeks (selected sites only) 
Arterial stiffness via pulse wave velocity (PWV) measured by arterial 
tomography or ultrasound at baseline, 12 and 24 weeks (selected sites only) 
Arterial stiffness via augmentation index  measured by arterial tomography at 
baseline, 12 and 24 weeks 
Deep tissue oxygenation  (hemoglobin concentration and SO2) via near infrared 
spectroscopy at baseline, 12 and 24 weeks 
Blood viscosity  at baseline, 12 and 24 weeks (selected sites only) 
Lipid panel : total cholesterol, LDL-C, HDL-C, triglycerides, Blood fibrinogen at 
baseline, 12 and 24 weeks 
Inflammatory markers : C-Reactive Protein (CRP), Lp-PLA2 and MPOS at 
baseline, 12 and 24 weeks  
CBC: including Red Cell Distribution Width (RDW) & Hemoglobin at baseline, 12 
and 24 weeks 
Presence  
Difference in change from baseline  at 12 and 24 weeks in the Behavioral Assessment  measured 
via Neuropsychiatric Inventory (NPI) Agitation/Aggression. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 28 of 78Difference in change from baseline at 12 and 24 weeks in balance, functional mobility, and fall-
risk assessment measured via Timed Up & Go (TUG) test and the Functional Reach Test . 
Time course comparative analysis  between treatment and active sham groups in ADAS Delayed 
Word Recall  (a sub-test of the vADAS cog) at baseline, 12 and 24 weeks. 
Time course comparative analysis  between treatment and active sham groups in ADAS Word 
Recognition  (a sub-test of the vADAS-cog) at baseline, 12 and 24 weeks. 
Comparison of ADAS-Cog12 scores at 12 weeks, 24 weeks, 9 months, and 12 months between 
an external control arm of digital twins and each of the actual treatment and active sham 
groups . An external control arm of digital twins (digital subjects with the same baseline 
characteristics as actual study participants) simulates, at a subject level, clinical trajectories of 
actual study subjects under the counterfactual scenario of no treatment.  Ten digital twins will 
be created for each subject enrolled in the study.  The digital twins will be generated by a model 
of AD progression developed by Unlearn.AI Inc., based on data from the control arms of 18 AD 
and MCI phase II and III clinical trials (4897 subjects) (Neville, et al., 2015). This model was 
shown to generate digital controls which are statistically indistinguishable from those of actual 
control subjects across a wide variety of clinical measures included in the model (Fisher, et al., 
2019; Walsh, et al., 2020).  The treatment effect vs. external control group will be estimated for 
each of the actual study arms (treatment and active sham), including testing the hypothesis that 
there is no treatment effect in the active sham arm vs. external control arm. 
6.STUDY ENROLLMENT AND WITHDRAWAL 
6.1 Inclusion Criteria
Subjects will meet all inclusion criteria and none of the exclusion criterion. The study is open to both 
genders and members of all minority groups. Subjects enrolled into the study will: 
1.Be 55-85 years of age at the time of signing the informed consent 
2.Be able to provide consent or have legally authorized representative/caregiver who can provide 
consent 
3.Be able to read and write in English or Spanish  
4.Have a clinical diagnosis consistent with 2011 NIA-AA “core clinical criteria” guidelines for: (i) 
The diagnosis of dementia due to Alzheimer’s disease or (ii) The diagnosis of mild cognitive 
impairment due to Alzheimer’s disease: 
MOCA score of greater than or equal to 11 
All required checkboxes within the study checklist for “The diagnosis of probable AD 
dementia” must be “yes” or 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 29 of 78All required checkboxes within the study checklist for “The diagnosis of mild cognitive 
impairment due to Alzheimer’s disease” must be “yes” 
5.Stable medications for past 30 days and plan to remain on stable medications for the first 24 
weeks of study participation for treatment of chronic conditions
6.Subject should have a caregiver, study partner or companion (which can be a domestic party) 
who can complete the study assessments. The assessments may be conducted over the phone if 
they don’t accompany the participant 
7.Must have the potential to improve by at least 2 points or more in the vADAS-COG  
6.2 Exclusion criteria
Subjects who meet any of the exclusion criteria will be excluded from study participation. The 
investigator shall exclude subjects with the following conditions: 
1.Unwilling or unable to participate in study procedures 
2.Weight >297 lbs. or >135 kg at screening 
3.Major confounding neurodegenerative or psychiatric disorder unrelated to the condition under 
study, including: 
a.History of clinically-evident stroke 
b.Current uncontrolled epileptic seizures or epilepsy 
c.Multiple Sclerosis or Parkinson’s Disease 
d.Current clinically significant major psychiatric disorder (e.g., Major Depressive 
Disorder) according to DSM-V criteria or significant psychiatric symptoms (e.g., 
hallucinations) that could impair the completion of the study 
4.Anyone with active or history of cerebral hemorrhage including subdural & subarachnoid or 
cerebral aneurysm 
5.Evidence of any of the following (based on Section 4.1.1(D) of the 2011 NIA-AA guidelines on 
The diagnosis of dementia due to Alzheimer’s disease): 
a.Substantial concomitant cerebrovascular disease, defined by a history of a stroke  
temporally related to the onset or worsening of cognitive impairment; or the presence 
of multiple or extensive infarcts or severe white matter hyperintensity burden 
b.Core features of Dementia with Lewy bodies other than dementia itself 
c.Prominent features of behavioral variant frontotemporal dementia 
d.Prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic 
variant primary progressive aphasia 
e.Evidence for another concurrent, active neurological disease, non-neurological medical 
comorbidity or use of medication that could have a substantial effect on cognition 
6.In the opinion of the investigator, any current clinically-significant systemic illness or medical 
condition that is likely to result in deterioration of the subject’s condition, affect the subject’s 
safety during the study, or to be incompatible with performance of the study procedures, 
including: 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 30 of 78a.History of head trauma with a diagnosis of moderate to severe traumatic brain injury 
b.Known current substantially elevated intracranial pressure 
c.Known current significant sleep deprivation 
d.Known history (within five years) or current significant drug abuse or alcoholism 
7.Any contraindication for MRI such as insulin pumps or pacemakers, including dual chamber 
pacemakers where atrial pacing may interfere with RenewTM NCP-5 inflation timing sequence 
8.Hypotension as defined as <80/50 blood pressure at the time of screening 
9.Ongoing uncontrolled severe hypertension (≥ 180 mmHg systolic or ≥ 110 mmHg diastolic 
10.Heart rates < 35 or >125 beats per minute (BPM) at screening 
11.Current uncontrolled arrhythmia. Controlled arrhythmia should have beat-to-beat, cycle-length 
variability less than ±25% at rest. 
12.Current congestive heart failure  
13.Cardiac catheterization within two weeks, any surgical intervention within six weeks before 
RenewTM NCP-5 treatment or a hip or knee replacement within 3 months as long as rehab is 
complete and symptoms have resolved 
14.Known presence of abdominal aortic aneurysm 
15.Existing aortic insufficiency grade II or higher (regurgitation can prevent diastolic augmentation) 
16.Current or past venous thrombosis or thromboembolism 
17.Current limiting peripheral vascular disease with history strongly suggestive of lower extremity 
ischemia or claudication, arterial occlusive disease (aortoiliac, ileofemoral, or femoral popliteal) 
18.Demonstrable deficiency in sensation in lower extremities as a result of diabetes or other 
medical condition 
19.Current bleeding disorders  
20.Current use of major anti-coagulation therapy (such as Heparin therapy or Coumadin® therapy) 
with INR > 1.5  
21.Current severe pulmonary disease that prevents the subject from lying supine
22.Presence of local infection, vasculitis , burn, open wound, or bone fracture on any limb which 
would prevent the ability to perform the RenewTM NCP-5 treatment 
23.Current use of medications that in the investigator’s judgement are incompatible with the study 
goals 
24.Significant changes in existing medical plans for treatment of cognitive impairment or dementia 
in last three months and/or or planned changes during the trial  
25.Presence of any of the contraindications for using the RenewTM NCP-5 device 
26.Athletic injuries, including Charley horses, pulled muscles and/or edematous muscles; 
necrotizing cellulitis in the past 30 days which would prevent the ability to perform the RenewTM
NCP-5 treatment (evaluate and treat prior to RenewTM NCP-5 treatment)  
27.Unwilling or unable to maintain stable exercise regimen throughout the trial 
28.Participation in any clinical drug trial 30 days or five half-lives, whichever is longer, prior to 
screening visit 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 31 of 7829.Use of any device to increase cerebral blood flow in the past 30 days 
30.History of claustrophobia 
31.Subject unable to lay supine for 90 minutes 
6.3 Recruitment and Retention 
The study will enroll 100-250 subjects. Up to 16 sites will enroll at least one subject, and up to two will 
be international sites. A maximum of 50 subjects will be enrolled at a single site. Subjects will participate 
in the study for up to 13 months (up to 28 days screening, 24 weeks treatment and 6 months follow-up) 
and the study will continue for approximately 36 months. 
Subjects will be recruited from the clinics and outpatient practices of the investigators participating in 
the study, referrals from community-based practices and from recruitment efforts. Study staff will be 
trained in approaches to recruitment and will be provided with flyers and brochures with patient 
information. Announcements will be placed on relevant websites. Research staff will provide support 
and education to the family/caregivers and ensure they understand the study and its potential benefits. 
A pre-screening questionnaire may be used to identify potential subjects who will be invited for an in-
person screening visit. Eligible subjects will be randomized at multiple sites into the study. 
Ongoing contact with the subject and caregiver during the treatment phase will be maintained, as the 
subject will receive treatments up to five days per week. Missed appointments will be followed up by 
phone calls to understand reasons for missing the treatment and support will be provided in the form of 
transportation, or other needs. After the intense initial phase, the subjects will be seen less frequently, 
but the sites will maintain contact with the subject through mail, email, text message and phone calls as 
needed. 
6.4 Withdrawal or Termination
After randomization, all treatment subjects will have an initial four treatments (which are part of the 
planned 35 treatments) in which the PSI will be gradually increased to maximum tolerability with the 
goal of reaching 3-6 PSI by the fifth treatment. Subjects are not to be terminated if they cannot reach 3-
6 PSI. Each treatment session will last for 60-minutes and a treatment session 30 minutes or more (≥ 30 
minutes) will be considered as a completed session.   
The investigator can decide to withdraw a subject if any clinical adverse event, laboratory abnormality, 
or other medical condition or situation occurs such that continued participation in the study would not 
be in the best interest of the subject. Further, if a subject meets an exclusion criterion that precludes 
further study participation, she/he will be withdrawn from the study. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 32 of 78Subjects are free to withdraw consent and discontinue participation at any time. Their decision to do so 
will not affect their ability to receive medical care or lose any benefits to which they are otherwise 
entitled.  
All withdrawn subjects will be encouraged to complete study assessments at 6, 12, 18, 24 weeks, 9 and 
12 months/end of study assessments and final MRI. Safety follow up procedures to capture adverse 
events, SAE or unanticipated problems will be initiated. 
If the study is temporarily suspended or terminated early, written notification documenting the reason 
for study suspension or termination will be provided by the terminating party. The PI will inform the IRB 
and sponsor and provide the reason for termination or suspension. Determination of unexpected or 
significant risks to subjects, demonstration of efficacy, insufficient compliance to protocol requirements, 
determination of futility or incomplete data are some of the potential reasons for termination or 
suspension of the study. Enrolled subjects will be followed up to week 24 if the trial is terminated early. 
7.DEVICE 
Details about the description, operation, preparation and use of the RenewTM NCP-5 device are found in 
a separate Training Manual. 
7.1 Device Description
The RenewTM NCP-5 device used in the study has been FDA cleared under K152115. The RenewTM NCP-5 
device has the following major components: a switch panel, a foldable treatment bed, main unit, and a 
set of patient cuffs. During RenewTM NCP-5 treatments, the patient’s lower extremities are wrapped in 
compressive pneumatic cuffs applied to the calves, lower thighs, and buttocks. The device is a 
microprocessor-controlled system that sequentially inflates then deflates three pairs of air cuffs, which 
compress vascular beds in the muscles of the calves, thighs, and buttocks in synchrony with the heart 
cycle to achieve the desired therapy. The attached computer provides real time monitoring of: heart 
rate; Inflation and deflation time; treatment time; treatment pressure; and peak diastolic/peak systolic 
ratio (P/P). The PC provides synchronous display of the ECG signal, the inflation/deflation signal, and the 
pulse wave (Renew Group Private, Ltd., 2017). 
Input and data from the ECG, plethysmograph, and the pressure/vacuum transducers are processed by 
the microprocessor to control the valve timing and air pressure in the tank that is delivered to the cuffs. 
Treatment pressure is monitored with an internal pressure sensor and the operator-selected set point 
maintained by a closed-loop control system. Valve inflation and deflation timing is also set by the 
operator based on the relative position of the R-wave of the patient’s ECG. Detailed description of the 
device is also shown in Appendix D, the Investigator Brochure. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 33 of 787.2 Acquisition of Device
The RenewTM NCP-5 system arrives in a wooden crate as a single shipment consisting of: NCP-5 unit, 
Laptop PC, and Accessories (cables, hoses, supplies). The unit is also the patient treatment platform. 
Delivery includes factory installation and set-up. Before the technician departs from the installation site, 
s/he completes a checklist and the site manager signs confirmation of the quality control/assurance 
steps taken by the technician. 
7.3 Storage and Stability
The RenewTM NCP-5 system should be stored at room temperature in a secure location. It does not 
require calibration and can be serviced by an approved technician, as needed. 
7.4 Preparation
The technicians will follow the preparation and treatment instructions as outlined in the RenewTM NCP-5 
training manual.  
7.5 Dosing and Administration
The subject is positioned lying flat on the foldable treatment bed and pneumatic, blood pressure like 
cuffs, are placed on his/her legs: calf, lower thigh and buttocks. They are connected to monitors that 
record heart rate and rhythm. The cuffs will be inflated and deflated based on the actions of the 
subject’s heart (between heartbeats). Compression pressure will be given at different levels depending 
on whether the subject is assigned to the treatment group or the active sham group. The subject’s 
overall ability to tolerate the treatment may impact the pressure applied. The operator of the device will 
increase pressure progressively and assess the subject’s level of discomfort. 
For all treatment subjects, the first four sessions represent the escalation phase. There will be a 5-
minute ramp up period where the pressure is increased 1PSI / min until the desired pressure is reached. 
The goal for the treatment group will be at least 2.5 PSI (pounds per square inch) for the first treatment, 
and then escalate the pressure gradually through the fourth session at which time the goal for the 
subject should be at least an average of 3 PSI/session. For all sessions, the subject should reach the 
highest tolerable pressure. Patients are not to be terminated if they can't reach 3-6 PSI. Each treatment 
session is 60 minutes however, if necessary, on an as-needed basis, a treatment session of 30 minutes or 
more (≥ 30 minutes) will be considered as a completed session. 
After the fourth session, the operator shall continue to slowly increase the pressure to give the subject 
time to adapt to the rising pressure in order to reach the maximum level that the subject finds 
comfortable with a goal of reaching 3-6 PSI or the highest tolerable pressure. The operator may alter the 
pressure in the event that a subject becomes uncomfortable after the start of treatment. For both 
treatment arms, the RenewTM NCP-5 operator should record the average compression pressure and 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 34 of 78maximum diastolic augmentation (the ratio of diastolic peak height to systolic peak height – P/P) during 
each treatment session just before (1-2 minutes) reducing the pressure at the end of treatment. 
Active sham control subjects will receive the same initial and maintenance treatment regimens as 
treated subjects except that the pressure will not exceed an average of 0.5 PSI over all treatments. 
Active sham subjects will undergo cognitive testing and imaging at the same time points as treated 
subjects. The purpose of the active sham RenewTM NCP-5 treatments is to give the subject an experience 
that seems to be an authentic treatment but, instead, provides minimal or no therapeutic benefit.  
For a active sham treatment, the subject is handled exactly as in a typical therapeutic treatment (vitals, 
wrapping of cuffs, etc.), but with two important differences: 
The treatment pressure is set to a maximum of 0.5 psi and is kept there for the duration of the 
active sham treatment. Note that it may be difficult to maintain the pressure at exactly 0.5 psi. 
Although all attempts should be made to use a maximum of 0.5 psi, occasional, transient 
excursions as high as 1.0 psi are permissible. 
Although the subject will have ECG electrodes attached to his/her chest as per usual RenewTM
NCP-5 protocol, the cable from those leads will not be connected to the RenewTM NCP-5 
machine. Instead, the RenewTM NCP-5 machine will be connected to an ECG simulator hidden 
under the plastic “skirt” of the machine. 
The ECG simulator is used to drive the RenewTM NCP-5 machine, rather that the subject’s actual ECG. 
This causes the "squeezes" applied by the machine to be out of sync with the patient’s heartbeat, thus 
minimizing any possible therapeutic effect. 
ECG simulator settings are as follows: 
Normal sinus rhythm (NSR) 
Heart rate = 70 bpm 
Amplitude – 4 mV 
Sleep – No 
Each treatment session will last for 60-minutes. During the initial treatment period (~1-12 weeks) 
subjects should be treated five days per week but at a minimum receive treatments three days per 
week. A maximum of 35 treatments may be administered in the initial 12-week treatment period. Once 
the first 35 treatments have been administered, the subjects will start the maintenance period where 
subjects will receive two treatments per week. For subjects who are unable to complete 5 treatment 
days per week, the treatments should be spread-out as much as possible.  In order to complete 5 
treatments per week, it is permissible for those subjects to have 2 treatments per day as long as there 
are no more than 3 days between treatments. If two treatments are conducted on the same day, 
subjects will need to wait a minimum of one-hour between treatments. Treatments should be 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 35 of 78completed per the above schedule. The schedule may be adjusted due to holidays or extenuating 
circumstances.  If subjects need to miss visits during any particular week, then treatments should be 
added to the week prior to or after the missed visits.  A total of 35 treatments must be completed within 
the 12-week period.  More than 7 days between treatments would be considered a protocol violation. 
Once the first 35 treatments have been administered, subjects will start the maintenance period where. 
During the maintenance period, subjects should be treated two days per week, one session per day with 
a minimum of two full days between each treatment. Subjects may be rescheduled on an as needed 
basis as long as 6 treatments are maintained within 3-week period. Rescheduling should be kept to a 
minimum and all efforts should be made to have treatments every week.  
Assessment visits should occur the day following the last treatment session but no later than 2 days (48 
hours) after the last treatment. 
If necessary, on an as-needed basis, a treatment session of 30 minutes or more (≥ 30 minutes) will be 
considered as a completed session.  
Subjects should not eat 60 minutes prior to treatment but if necessary, a light snack is acceptable. 
Cognitive testing will occur at baseline, weeks 6, 12, 18, 24, 9 and 12 months after baseline. 
Assessments should be performed the day after the last treatment but no more than 48 hours after the 
last treatment. For all cognitive testing days, the vADAS-Cog will be administered first and all 
assessments should be done before 3:00 PM. 
If assessment occurs on the same day as treatment, the following must be observed: 
Assessments must occur after  treatment 
vADAS-Cog must be the first assessment performed 
Assessments must occur prior  to labs and imaging 
Assessments must be completed before 3:00 PM 
7.6 Duration of Therapy
Subjects will receive thirty-five 60-minute RenewTM NCP-5 sessions during the 7-to-12-week initial 
treatment period, and then transition to a lower frequency maintenance period (twice a week) for a 
total treatment period of 24 weeks.
7.7 Tracking of Therapy
The operator uses the PC to enter patient demographics, record pre and post-treatment data, and 
process data acquired by the microprocessor module to display user feedback for the RenewTM NCP-5 
treatment on the LCD showing treatment parameters and patient waveforms during use. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 36 of 788.STUDY PROCEDURES AND SCHEDULE 
The investigator brochure (IB) will be supplied to sites as a separate document and is attached to this 
protocol as Appendix D. 
8.1 Study Specific Procedures 
Medical and Treatment History –  The subject’s medical and treatment history including past 
procedures will be obtained by interview and review of medical records. The investigator will 
review body systems, identify start/stop dates, and determine if the condition is ongoing. 
Exclusion criteria identify conditions and timeframes that will exclude the subject from 
participation.
Medication history –  Medications and supplements are expected to have been stable for 30 
days prior to study start and remain stable over the first 24 weeks of the study for chronic 
conditions. All medications and supplements will be recorded and their impact on the study will 
be assessed . 
Physical examination – A physical examination, including a brief neurological exam, will be 
performed to ensure subjects do not exhibit any exclusion criteria and are healthy enough to 
participate in the study. A second physical exam will take place at end of study.
Exercise history and Mobility Assessments – Subjects will confirm their level of exercise, 
including cognitive exercises such as language exercises, Sudoku puzzles or online brain training 
programs (e.g. Lumosity), number of times per week, and length of each exercise session. The 
aim is to maintain the same level of exercise over the course of the study. Mobility assessments 
will be performed to assess the participant’s balance, functional mobility, and fall risk.
oTimed Up & Go (TUG) Test –  A common clinical screening tool used to assess a 
patient’s mobility, balance, gait speed, and fall risk. The patient is timed while they 
rise from an arm chair, walk to a line on the floor three meters away, turn around 
and walk back to the chair and sit down again. The subject wears his regular 
footwear and uses his customary walking aid (cane or walker) if necessary.
oFunctional Reach Test – A valid and reliable measure used to identify deficits in 
dynamic balance and fall risk. It is a single-task, dynamic measure of the difference 
in arm’s length and maximal forward reach using a fixed base of support in the 
standing position.
Patient questionnaire – Patient self-evaluation questionnaire
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 37 of 78Health Resource Utilization Questionnaire – RUI – (Resource Use Inventory)- Patient self-
reported questionnaire designed to assess health related services the patient has used during 
the course of the study.
Vital signs – An electrocardiogram will be performed at screening to ensure the subject is 
healthy enough to participate in the study and does not demonstrate any cardiovascular 
problems. Blood pressure, heart rate and respirations will be recorded before and after each 
RenewTM NCP-5 treatment and at every visit. 
Radiographic and imaging assessments – Magnetic resonance imaging (MRI) will be performed 
to rule out other brain pathology including evidence of infection, infarction (including multiple 
lacunas in a critical memory structure), or other focal lesions. If a history of cerebral aneurysm is 
suspected, the subject will be referred to their primary physician and/or neurologist. Central 
Reading of the MRI’s will be conducted at MGH. In addition, MRI will be performed at screening 
and at 12 weeks, 24 weeks and 12 months to assess hippocampal volume and regional cerebral 
blood flow changes over time. Freesurfer software will be used to measure volume (Schmidt, 
Storrs, et al., 2018). Studies show that Hippocampal atrophy associated with episodic memory 
declines over time as observed for word fluency, fluid IQ (block design) and processing speed. 
These changes are significant in subjects 65-80 years old and noted in 55- 60-year-old subjects 
(Gorbach, Pudas, et al., 2016). 
At select sites, MRI will be used to assess global cerebral blood flow and white matter 
hyperintensities (WMH) at initial screening, 24 weeks, and 12 months. WMH reflects cerebral 
hypoperfusion and small vessel disease and is a covariate for vascular disease. WMH lesions are 
tied to disease progression and decreased cerebral blood flow. 
At select sites, Doppler ultrasound will be performed to assess Pulse Wave velocity, flow 
mediated dilation, endothelial function, and arterial stiffness. KU uses the Moor imaging 
product to monitor deep tissue oxygenation including SO 2, deoxygenated hemoglobin, and 
oxygenated hemoglobin.  
Central reading of all MRI images will be performed at MGH, based on an imaging protocol 
which will be provided as a separate document. They propose the use of a Siemens Skyra as the 
platform for imaging to ensure reproducibility and comparability and have developed an 
automated protocol to ensure standardization across sites. If other platforms are used, MGH 
will adapt the protocol for their use. It is imperative that, at the very least, the subject’s imaging 
will be performed on the same machine.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 38 of 78Eligibility Checks and Cognitive Assessments – Cognitive assessments should be performed as 
early in the day as possible (before 3:00 PM) and at approximately the same time every 
assessment. The vADAS-Cog will always be the first assessment performed. Assessments can be 
performed on the same day as RenewTM NCP-5 treatment as long as they are performed after 
treatment is completed. If assessments are not performed on the same day as treatment, it is 
recommended that subjects come in the day following treatment for all assessment testing but 
no later than 2 days (48 hours) post last RenewTM NCP-5 treatment. Psychometricians/designees 
will be blinded to treatment. 
oMMSE2 – The MMSE2 is a brief assessment instrument used to assess cognitive function 
in geriatric patients. The MMSE2 is used to screen for cognitive impairment and as a 
measurement of cognitive change over time. It is described in detail in Section 2.  
oLogical Memory Sub-test of the Wechsler Memory Scale – is a standardized assessment 
of narrative episodic memory. A short story is orally presented and the subject is asked 
to recall the story verbatim (immediate recall). Both Logical Memory I and Memory II 
will be administered. 
oMOCA – The Montreal Cognitive Assessment is a widely used cognitive assessment for 
patients with Mild Cognitive Impairment due to Alzheimer’s Disease or Mild Dementia of 
the Alzheimer’s Type. It includes a memory recall test, visuospatial abilities, executive 
function, attention, concentration, working memory, naming and orientation to time and 
place.  
oCardiovascular Risk Assessment  (CVR) – is a tool to assess the subject’s cardiovascular 
risk which will be used to stratify subjects at baseline into low/medium risk (< 20% 10 
year risk) vs. high/very high risk (> ≥20% 10 year risk).  
oHachinski Scale – is a tool used to identify a likely vascular component once a dementia 
diagnosis has been established. Vascular changes more commonly coexist with 
Alzheimer’s plaques. Scores reflect attention and executive function. 
ovADAS-Cog –The vADAS-Cog is made up of ADAS-Cog14 plus three additional tests: the 
symbol digit test (the number of correct responses in 90 s); the digit span backward test 
(the number of digits recalled backwards); and the verbal fluency test (animal category 
in one min). The ADAS-Cog is an instrument devised to assess the severity of cognitive 
impairment in patients with AD. The scale includes short neuropsychological tests in 
which the patient performs simple tasks such as word recall, word recognition, and 
constructional praxis. The cognitive section of the ADAS consists of II items, which assess 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 39 of 78the following: language (aphasia), and motor skills (praxis ). Rosen, Mohs, et al. (1984) 
evaluated the test-retest and interrater reliabilities of the individual scale items and the 
entire scale in patients with dementia of the Alzheimer's type. The ADAS was shown to 
be valid in the ability to detect patients with clinically diagnosed AD from matched non-
demented controls. Because both of the above cognitive and non-cognitive parameters 
are assessed, the ADAS is a reliable instrument for use in psychopharmacologic trials 
involving patients with AD.
oADCS-CGIC – assesses clinic global impression of change over time by patient/caregivers 
and clinicians as indicators of meaningful change and reflects observable changes. 
Subject should have a caregiver, study partner or companion (which can be a domestic 
party) and may conduct the assessment over the phone if they do not accompany the 
participant). 
oADCS-ADL – The ADCS-ADL is a set of informant-based items describing performance of 
activities of daily living assesses the subjects ability to eat, walk, bathe, groom, dress, and 
other activities of daily living independently by patients with AD. Questions are asked of 
the caregiver and are given in the form of an interview. Subject should have a caregiver, 
study partner or companion (which can be a domestic party) and may conduct the 
assessment over the phone if they do not accompany the participant). 
oTrail Making TEST A & B – Neuropsychological test of visual attention and task switching 
that assesses visual search speed, scanning, speed of processing, mental flexibility, and 
executive functioning. It is the most commonly used test in clinical practice to evaluate 
patients for MCI or mild AD.  
o2011 NIA-AA criteria –In 2011, the National Institute on Aging (NIA) at National 
Institutes of Health (NIH) and the Alzheimer's Association published revised guidelines 
(NIA-AA) for modernization of the diagnosis of Alzheimer's disease. In these guidelines, 
the workgroups identified Alzheimer's disease as a continuum with three distinct stages: 
Preclinical, Mild Cognitive Impairment and Dementia. Checklists to assist in 
standardizing assessments across sites used to differentiate MCI and dementia will be 
implemented in this study. 
Neuropsychiatric Inventory  (NPI) – A behavioral assessment used to assess dementia-related 
behavioral problems. The NPI is administered to caregivers of dementia patients. Screening 
questions are used to assess sub-domains of behavioral functioning such as, but not limited to, 
agitation/aggression, dysphoria, anxiety, irritability/lability, and appetite and eating 
abnormalities. Positive responses to these screening questions identify problems in the 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 40 of 78associated sub-domain. The caregiver is then asked to rate frequency, severity, and distress of 
symptoms in the related sub-domain. Higher scores are correlated to patients with dementia. 
8.2 Laboratory Evaluations
Comprehensive Metabolic Panel (CMP) – Blood test to assess levels of electrolytes, how well 
the kidneys and liver are working, and blood glucose. Includes 14 blood tests that provide 
information about the current health status of the patient. Performed at baseline to assess 
whether the subject is healthy enough to participate in the study. Performed at intervals during 
the study to confirm no change in subject’s health. Vitamin B12 and TSH will also be assessed. 
ApoE – Polymorphism of the apolipoprotein (ApoE) gene and its effect in modulating 
hippocampal change will be assessed. 
Lipid Panel – Provide a profile of cholesterol, HDL, LDL, and triglycerides to assess cardiac risk 
and general health of the subject 
Complete blood count (CBC) – Gives information about the cells in a patient’s blood, including 
hemoglobin, hematocrit, and white blood cells to assess patient’s general health. 
C-reactive protein (CRP) and Lp-PLA2 and MPOS – Blood markers for inflammation in the body. 
These inflammatory markers are implicated in the pathogenesis of AD and VD. CRP is a strong 
marker of vascular disease in early stages of the disease. 
Blood viscosity – AD patients have significantly increased whole blood viscosity which is 
correlated with disease severity.
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, your staff, and the applicable Institutional 
Review Board. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written 
authorization from the sponsor. 
Page 41 of 788.3 Study Schedule
Table 1: RenewTM NCP-5 Treatment Schedule
Treatment Schedule 
RenewTM NCP-5 initial treatment visits 3-5 treatments per week to 35 treatments 
RenewTM NCP-5 maintenance treatments 2 treatments per week as maintenance up to week 24  
Table 2: RenewTM NCP-5 Visit Schedule
Evaluation/ Procedure Screening Baseline Randomization
/ T1 Weeks 
1-6 Week 6 
Assessment Weeks 
7-12 Week 12 
Assessment Weeks 
13-18 Week 18 
Assessment Week  
19-24 Week 24 
Assessment 9 Month 
Assessment 12 Month / 
Early 
Termination 
Procedure Window by Study 
Day or Treatment Day Day -35 
to Day -7 Day -14 to 
Day -1 Day 1 Day 42  
(+/- 2 Days) Day 84 
(+/- 2 Days) Day 126  
(+/- 2 Days) Day 168 
(+/- 2 Days) Day 252  
(+/- 7 Days)  Day 365 
(+/- 7 Days)  
Informed Consent X 
MOCA X X X X 
Demographics X 
Medical, Treatment & 
Procedure History  X X******* 
Vitals** X X X X X X X X X X X X X 
EKG X 
Labs X X X X 
Physical Exam (including 
Neuro) X X 
Hachinski Scale Assessment X X X X 
2011 NIA Checklist 
Administration (MCI or AD 
checklist to be administered) X 
CVR Calculation X 
Exercise Regimen X X X X X X X 
TUG Test X X X X X X X 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, your staff, and the applicable Institutional 
Review Board. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written 
authorization from the sponsor. 
Page 42 of 78Evaluation/ Procedure Screening Baseline Randomization
/ T1 Weeks 
1-6 Week 6 
Assessment Weeks 
7-12 Week 12 
Assessment Weeks 
13-18 Week 18 
Assessment Week  
19-24 Week 24 
Assessment 9 Month 
Assessment 12 Month / 
Early 
Termination 
Procedure Window by Study 
Day or Treatment Day (Day -35 
to Day -7) Day -14 to 
Day -1 Day 1 Day 42  
(+/- 2 Days) Day 84 
(+/- 2 Days) Day 126  
(+/- 2 Days) Day 168 
(+/- 2 Days) Day 252  
(+/- 7 Days)  Day 365 
(+/- 7 Days)  
Functional Reach Test X X X X X X X 
Patient Questionnaire X X X X X X X 
vADAS-Cog**** X X X X X X X 
ADCS-CGIC**** X X X X X X X 
ADCS-ADL**** X X X X X X X 
Trail Making  
Test A & B  **** X X X X X X X 
Logical Memory I & II****  X X X X 
MMSE2 X X X X 
NPI X X X X X X X 
Health Resource Utilization 
Survey (RUI) X X X X X 
Patient Satisfaction Survey X 
Inclusion and Exclusion 
Eligibility Checks X X X 
Randomization X 
NCP-5 Treatment X X X X X 
MRI (including hippocampal 
volume)*** X X***** X****** 
Ultrasound/MOOR deep 
tissue oxygenation*** X X 
AE X X X X X X X X X X X X 
Concomitant Medications X X X X X X X X X X X X X 
Con-Treatments X X X X X X X X X X X X X 
Study Disposition X 
*Day 1 = first treatment day. All visit windows are based on the 1st treatment date 
**Vitals are pre & post treatment except for screening and Month 12/ET 
***The initial MRI will be performed after the participant meets the initial screening criteria. Only designated sites will perform MRI to assess regional CBF, regional brain volume, resting state connectivity and/or Ultrasound to 
assess Flow Mediated dilation, pulse wave velocity, AI, Transcranial Doppler, Cerebral artery blood flow, Moor deep tissue oxygenation.   
**** vADAS-Cog assessment MUST  be the first cognitive test administered, and all cognitive assessments MUST  be completed before labs and imaging. Cognitive tests can be administered on the same day as treatment visit but 
must be done before 3:00 PM and after  treatment is completed. 
***** MRI must be done after last treatment but may take place on or before the Week 24 assessment visit 
******MRI must be completed within 14 Days prior to the Month 12 Visit 
*******If not collected at screening visit 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 43 of 788.4 Study Visits
8.4.1 Screening (-35 to -7 days prior to baseline) 
Screening assessments ascertain whether the patient is eligible to participate in the study. Assessments 
that require the least imposition on the patient and the staff will be performed first to exclude patients 
before they are subjected to more demanding assessments. As necessary, screening may be performed 
on multiple visits. The MRI will be performed after the screening inclusion/exclusion criteria have been 
met. Assessments will be performed in the order noted on the time and events schedule: 
Obtain informed consent verified by signature on written informed consent 
Administer the MOCA 
Review demographics, medical/treatment history to determine eligibility based on 
inclusion/exclusion criteria 
Concomitant Medications and Treatments 
Perform vital sign check and EKG  
Draw blood for: 
oApoE  
oBlood CBC, CMP, lipid panel, fibrinogen, CRP, LP-PLA2, MPOS, lipoprotein particles, 
Blood viscosity, B12, TSH 
Perform physical (including neurological) examination to determine eligibility based on 
inclusion/exclusion criteria 
Completion of “core clinical criteria” checklist(s) for the 2011 National Institute on Aging (NIA)-
Alzheimer’s Association (AA) Guidelines on: (i) The diagnosis of dementia due to Alzheimer’s 
disease or (ii) The diagnosis of mild cognitive impairment due to Alzheimer’s disease 
Complete the Logical Memory I & II 
Administer the MMSE2 
Review inclusion/exclusion screening eligibility 
Perform MRI to rule out brain pathology, measure hippocampal volume and to assess 
exploratory endpoints (selected sites only). Brain pathology will include tumors, current or past 
bleeding, current or past aneurysms. The MRI should be done after the subject has been 
determined eligible to participate in the study. Initial screening MRI scan can be utilized if < 90 
days for subjects being re-screened. 
8.4.2 Baseline Visit (Day -14 – Day -1) 
Vital Signs 
Administer Hachinski 
CVR calculation 
Review exercise regimen 
Patient questionnaire 
Administer baseline cognitive assessments including: 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 44 of 78ovADAS-Cog (must always be administered first and before 3:00 PM) 
oADCS-CGIC for clinician and patient/caregiver 
oADCS-ADL 
oTrail Making A&B 
TUG Test 
Functional Reach Test 
Health Resource Utilization Survey - RUI 
NPI 
Review concomitant medication and treatments 
Collect adverse events 
Schedule study visits for eligible subjects  
Verify inclusion/exclusion criteria 
8.4.3 Randomization/First Treatment Day (Day 1) 
Randomization must occur after eligibility confirmation and prior to first treatment. The following 
assessments should be performed during this visit: 
Verify inclusion/exclusion criteria  
Randomize subject 
Review concomitant medications and treatments  
Collect adverse events 
Record vital signs (Pre & Post) 
Administer treatment (All treatment subjects will have an initial four treatments (which are part 
of the planned 35 treatments) in which the PSI will be gradually increased to maximum 
tolerability with the goal of reaching 3-6 PSI by the fifth treatment). 
For sites collecting data for exploratory endpoints, complete the following assessments: 
Ultrasound: Transcranial Doppler; cerebral artery blood flow 
Moor deep tissue oxygenation (selected sites only) 
8.4.4 Weeks 1-6 
Record vital signs (Pre & Post) 
Review concomitant medications and treatments 
Collect adverse events 
 During the treatment phase, administer treatments 5 days per week but at a minimum 3 days 
per week up to a maximum of 35 treatments total. (All treatment subjects will have an initial 
four treatments (which are part of the planned 35 treatments) in which the PSI will be gradually 
increased to maximum tolerability with the goal of reaching 3-6 PSI by the fifth treatment).
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 45 of 788.4.5 Week 6 – Day 42 (+/- 2 days) 
Cognitive assessments:  It is recommended that subjects come in the day following treatment 
for all assessment testing but no later than 2 days (48 hours) post last treatment. Administer 
cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
oTrail Making A & B 
Record vital signs (If non-treatment day) 
TUG Test 
Functional Reach Test 
NPI 
Exercise regimen 
Patient Questionnaire  
Review concomitant medications and treatments,  
Collect adverse events  
If treatment occurs on same day as assessments complete the treatment first 
oVitals (Pre & Post) 
oDuring the treatment phase, administer treatments 5 days per week but at a minimum 3 
days per week up to a maximum of 35 treatments total 
8.4.6 Weeks 7-12 
Record vital signs (Pre & Post) 
Review concomitant medications and treatments 
Collect adverse events 
During the treatment phase, administer treatments 5 days per week but at a minimum 3 days 
per week up to a maximum of 35 treatments total (or during maintenance, administer two 
treatments per week separated by at least 2 days up to 24 weeks) 
8.4.7 Week 12 – Day 84 (+/- 2 days) 
Cognitive assessments:  It is recommended that subjects come in the day following treatment 
for all assessment testing but no later than 2 days (48 hours) post last treatment. Administer 
cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 46 of 78oTrail Making A & B 
Record vital signs (If non-treatment day) 
TUG Test 
Functional Reach Test 
Health Resource Utilization Survey - RUI 
NPI 
Exercise regimen 
Patient Questionnaire 
Review concomitant medications and treatments,  
Collect adverse events  
If treatment occurs on same day as assessments administer treatment first  
oVitals (Pre & Post) 
oDuring the treatment phase, administer treatments 5 days per week but at a minimum 3 
days per week up to a maximum of 35 treatments total (or during maintenance, 
administer two treatments per week separated by at least 2 days up to 24 weeks) 
Draw blood for: 
oBlood lipid panel, CBC, fibrinogen, CRP, LP-PLA2, MPO, lipoprotein particles to include: 
LDL-P, Lp(a)-P, VLDL-P, IDL-P, ApoB, B12, TSH 
oBlood viscosity 
8.4.8 Weeks 13-18  
Record vital signs (Pre & Post) 
Review concomitant medications and treatments 
Collect adverse events 
Administer two treatments per week separated by at least 2 days as maintenance up to 24 
weeks 
8.4.9 Week 18 – Day 126 (+/- 2 days) 
Cognitive assessments:  It is recommended that subjects come in the day following treatment 
for all assessment testing but no later than 2 days (48 hours) post last treatment. Administer 
cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
oTrail Making A & B 
Record vital signs (If non-treatment day) 
TUG Test 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 47 of 78Functional Reach Test 
NPI 
Exercise regimen  
Patient Questionnaire 
Review concomitant medications and treatments  
Collect adverse events  
If treatment occurs on same day as assessments administer the treatment first  
oVitals (Pre & Post) 
oAdminister two treatments per week separated by at least 2 days as maintenance up to 
24 weeks 
8.4.10 Weeks 19-24  
Record vital signs (Pre & Post) 
Review concomitant medications and treatments 
Collect adverse events 
Administer two treatments per week separated by at least 2 days as maintenance up to 24 
weeks 
8.4.11 Week 24 – Day 168 (+/- 2 days) 
Cognitive assessments:  It is recommended that subjects come in the day following treatment 
for all assessment testing but no later than 2 days (48 hours) post last treatment. Administer 
cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
oTrail Making A & B 
oLogical Memory I & II 
MOCA 
Vital signs (If non-treatment day) 
Hachinski 
MMSE2 
TUG Test 
Functional Reach Test 
Health Resource Utilization Survey - RUI 
NPI 
Exercise regimen  
Patient questionnaire 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 48 of 78Review concomitant medications and treatments  
Collect adverse events  
If treatment occurs on same day as assessments administer the treatment first 
oVitals (Pre & Post) 
oAdminister two treatments per week separated by at least 2 days as maintenance up to 
24 weeks 
Draw blood for: 
oBlood lipid panel, CBC, fibrinogen, CRP, LP-PLA2, MPO, lipoprotein particles to include: 
LDL-P, Lp(a)-P, VLDL-P, IDL-P, ApoB, B12, TSH 
oBlood viscosity  
MRI (Must be done after last treatment but may take place on or before the Week 24 
Assessment Visit) 
For sites collecting data for exploratory endpoints, complete the following assessments: 
Ultrasound: Transcranial Doppler; cerebral artery blood flow 
Moor deep tissue oxygenation 
8.4.12 Month 9 (Week 36) – Day 252 (+/- 7 days) 
Administer cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
oTrail Making A & B  
oLogical Memory I & II 
MOCA 
Record vital signs  
TUG Test 
Hachinski 
Functional Reach Test 
Health Resource Utilization Survey-RUI  
NPI 
Exercise regimen  
Patient Questionnaire 
Medical History, if not collected at screening visit 
Review concomitant medications and treatments 
Collect adverse events 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 49 of 788.4.13 Month 12/Study Termination – Day 365 (+/- 7 days) 
Administer cognitive assessments including: 
ovADAS-Cog (must be administered first and before 3:00 PM; should be administered at 
the same time of day) 
oADCS-CGIC 
oADCS-ADL 
oTrail Making A & B 
oLogical Memory I & II 
MOCA 
Vital signs 
Physical Exam including neuro 
Hachinski 
TUG Test 
Functional Reach Test 
Health Resource Utilization Survey - RUI 
NPI 
Exercise regimen  
Patient Questionnaire 
Patient Satisfaction Survey 
MMSE2 
Review concomitant meds and treatments  
Collect adverse events  
Draw blood for: 
oBlood lipid panel, CBC, fibrinogen, CRP, LP-PLA2, MPO, lipoprotein particles to include: 
LDL-P, Lp(a)-P, VLDL-P, IDL-P, ApoB, B12, TSH 
oBlood viscosity  
MRI (Must be completed within 14 Days prior to the Month 12 Visit) 
Complete Study Disposition Form 
8.4.14 Early Termination Visit 
All procedures scheduled for the 12 month/final visit should be performed in the event of an early 
termination visit. The subject should be encouraged to complete these assessments. 
8.4.15 Study Disposition 
Subjects will be discharged from the study to their pre-study routine. Ideally, subjects will continue in 
the study to complete the assessments and the 12 month visit. All subjects in the active sham arm will 
be eligible to participate in an active treatment follow up study after completion of the 12 month visit. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 50 of 788.5 ONGOING ASSESSMENTS
8.5.1 Concomitant Medications, Treatments and Exercise 
Subjects will be expected to be on stable medication for 30 days prior to study start and through the 
first 24 weeks of the study for chronic conditions. Changes in concomitant medications will be recorded. 
Treatment for adverse events will be recorded. The current use of medication that in the investigator’s 
judgement are incompatible with study goals will be prohibited and may result in the subject’s 
withdrawal from the study. Subjects should not begin any other treatments that, in the investigator‘s 
judgement may affect cerebral blood flow. 
Subjects will be requested to maintain their pre study exercise regimen throughout the first 24 weeks of 
the study. Exercise level will be assessed at baseline, 6, 12, 18, and 24 weeks, 9 months and 12 months. 
8.5.2 Laboratory Evaluations
Laboratory evaluations will occur at all the time points specified in the time and events schedule . The 
laboratory evaluations that will be performed are listed in Figure 2 .
Figure 2: Laboratory evaluations to be performed 
Abnormal laboratory test results of a magnitude deemed clinically significant by the investigator will be 
repeated as soon as possible (preferably within 48 hours) to rule out laboratory error. For tests where 
there is a persistent abnormality, repeat analyses shall be performed until the cause is determined and 
return to baseline occurs or the investigator deems the abnormality to be of no clinical significance. If 
these values are deemed clinically significant then these tests should be discussed with the medical 
monitor. If these abnormalities are accompanied by clinical symptoms, then these should be captured as 
AEs.Blood Chemistry
Sodium 
AST  
ALT
Total cholesterol
Triglycerides
Total proteinPotassium 
Glucose 
Creatinine 
Serum calcium 
Chloride 
BicarbonateBlood urea nitrogen  
Total bilirubin  
Albumin
Globulin 
B12 
TSH
Hematology
Hemoglobin 
Hematocrit 
PlateletsWhite blood cell count total and differential
Red blood cell count 
Exploratory Labs 
ApoE 
 Fibrinogen 
Lipid panelCRP 
LP-PLA2 
MPOS Blood viscosity 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 51 of 78A central laboratory will be used in this study. All details regarding the collection, shipment of samples, 
reporting of results and alerting extreme values will be provided by the central laboratory and compiled 
in a Laboratory Manual . 
8.5.3 Vital signs
The following vital signs assessments should be performed at Screening, Baseline, and at all visits 
(including early discontinuation):
Height- at screening visit only 
Weight 
Body temperature  
Respiratory  rate 
Heart rate 
Blood pressure (sitting after 5 minutes on assessment visits, Supine after five minutes on 
treatment visits).
8.5.4 Physical examination
Information collected during the physical examination will be recorded in the source documentation and 
subsequently on the Case Report Forms (CRF). 
8.5.5 Electrocardiogram
A 12-lead EKG will be performed and documented in the patient's medical chart at screening to ensure 
the patients does not have any contraindications for participation in the study. The investigator will 
review the ECG for eligibility criteria and sign/date the ECG report. 
9.SAFETY ASSESSMENTS
Safety will be monitored throughout the trial as follows: monitoring and recording of anticipated 
adverse effects, unanticipated adverse effects (UAEs), serious adverse effects, unanticipated adverse 
device effects (UADEs), the assessment of laboratory parameters, and vital sign measurements. 
9.1 Adverse  Events
An adverse event (AE) is any untoward medical occurrence experienced by a subject in conjunction with 
their participation in a clinical trial regardless of whether the event is related to the procedure or study 
device. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated 
with the use of an investigational device whether or not it is related to the investigational device. This 
includes any condition that is new in onset (not present prior to study treatment) or aggravated in 
severity or frequency from the baseline condition, any condition resulting from concurrent illness, 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 52 of 78reactions to concomitant medications, progression of disease states, and also includes abnormal lab test 
results if associated with clinical signs or symptoms judged by the investigator to be clinically significant.
All AEs that occur after the consent form is signed must be reported in the AE section of the CRF. 
Documentation for all AEs should contain the Adverse Event (medical condition), the date the AE started 
and if applicable, the stop date; the preliminary assessment of the relationship to study treatment ; any 
action taken with regard to study treatment; the outcome  of the event; whether the event was 
serious and if so, whether the event was anticipated or unanticipated; and whether treatment was 
required. 
For purposes of this study, a Serious Adverse Event (SAE) is defined in accordance with ISO 14155-
2011(en), Clinical Investigation of Medical Devices, as an adverse event that, in the view of the 
Investigator or the sponsor: 
Led to death 
Led to serious deterioration in the health of the subject that resulted in: 
i.Inpatient hospitalization or prolong hospitalizations 
ii.Life threatening illness or injury  
iii. Permanent impairment of a body structure or a body function 
iv. Medical/Surgical intervention to prevent one of the outcomes listed in line ii. or iii. above 
The sponsor is using the above ISO-14155-2011(en) definition of a SAE as an extra safety precaution in 
this study since no definition of “serious adverse effect” exists in Federal regulations governing medical 
device clinical trials, 21 CFR Part 812, Investigational Device Exemptions. 
An unanticipated adverse device effect (UADE) is defined, in 21 CFR Part 812.3(s) as any serious 
[“serious” as defined above and in ISO14155-2011(en)] adverse effect on health or safety, or any life-
threatening problem or death caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the protocol or 
investigational plan (e.g., Investigators Brochure, Product Labeling, Informed Consent 
Document etc.) or any other serious problem associated with a device that relates to the 
rights, safety or welfare of the subject. Unanticipated adverse device effects will be collected 
in an ongoing fashion during the study and will be entered into a separate safety database. 
All adverse events that do not meet any of the criteria for SAEs or UADEs should be regarded as non-
serious adverse events and/or an anticipated AE and will be documented, and subsequently reported, at 
least annually to the IRB and Sponsor.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 53 of 78Progression of disease reflects lack of therapeutic efficacy and should not be treated as serious adverse 
events. However, other events or complications meeting the criteria for serious adverse events should 
be considered as a serious adverse event and should be reported to the IRB regardless of presumed 
relationship to the investigational treatment. 
All subjects who have been exposed to study treatment will be evaluated for adverse effects. All adverse 
effects will be evaluated beginning with onset, and evaluation will continue until resolution or recovery 
is observed or until the Investigator determines that the participant’s condition is stable, whichever is 
earlier. The Investigator will take all appropriate and necessary therapeutic measures required for 
resolution of the adverse effect. Any medication necessary for the treatment of an adverse effect must 
be recorded on the study Concomitant Medication form. If more than one distinct adverse effect occurs, 
each event will be recorded separately. 
9.2 Adverse Event Assessment
All adverse events (AE), observed or reported, will be initially assessed by the Investigator or his/her 
medically qualified designee, and recorded on the study Adverse Effect Form according to the protocol 
and the Manual of Procedures. The need to capture AEs is not dependent upon whether or not the 
clinical event is associated with the use of the study treatment. 
Severity will be assessed using the following definitions: 
Mild:  Aware of sign or symptom, but easily tolerated 
Moderate: Discomfort sufficient to cause interference with usual activity 
Severe:  Incapacitating, with inability to work or do usual activity 
The relationship to Investigational Treatment will be assessed by the Investigator using the following 
criteria: 
Not 
Related Evidence exists that the adverse event definitely has a cause other than the 
study treatment (e.g. pre-existing condition or underlying disease, 
intercurrent illness, or concomitant medication) and does not meet any 
other criteria listed.  
Suspected Ther e is a reasonable possibility that the treatment caused the adverse 
event. “Reasonable possibility” means there is evidence to suggest a causal 
relationship between the treatment and the adverse event. A causal 
relationship requires a temporal relationship to exist between the adverse 
event onset and administration of study treatment.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 54 of 78Probably 
Related Strong evidence exists that the study treatment caused the adverse event. 
There is a temporal relationship between the event onset and 
administration of the study treatment. There is strong therapeutic evidence 
that the event was caused by the study treatment. The participant’s clinical 
state and concomitant therapies have been ruled out as a cause.  
All subjects who have been exposed to study treatment will be evaluated for adverse effects. All adverse 
effects will be evaluated beginning with onset, and evaluation will continue until resolution or recovery 
is observed or until the Investigator determines that the participant’s condition is stable, whichever is 
earlier. The Investigator will take all appropriate and necessary therapeutic measures required for 
resolution of the adverse effect. Any medication necessary for the treatment of an adverse effect must 
be recorded on the study Concomitant Medication form. If more than one distinct adverse effect occurs, 
each event will be recorded separately. 
9.3 Adverse Event Reporting
9.3.1 Adverse Event Reporting 
The study period during which adverse events must be reported is defined as the period from signing 
informed consent to the end of the study treatment follow-up (Month 12). If an adverse event is 
unresolved by the day of the 12-month data collection visit, and it is possible to follow the participant 
thereafter, this will be attempted for 30 days after the participant’s last study treatment. 
9.3.2 Reporting of Unanticipated (Serious) Adverse Device Effects, Serious Adverse Events, or 
Device Deficiencies 
Device Deficiency (DD) is the inadequacy of an investigational medical device related to its identity, 
quality, durability, reliability, safety or performance with or without patient involvement. This may 
include malfunctions, misuse or use error, or inadequacy in the information supplied by the 
manufacturer. 
All DDs, Serious Adverse Events (SAE), whether Anticipated or Unanticipated, which occur during the 
study, including death, must be reported in writing within 3 working days of the site becoming aware of 
the event.  
The local site Investigator must provide information on the SAE in a written narrative form, with as 
much information as possible. This should include a copy of the completed study Serious Adverse Effect 
form, and any other diagnostic information that will assist the understanding of the event. In the case of 
hospitalization, the de-identified admission report and if possible, the discharge summary should be 
obtained and submitted to the pharmacovigilance team (MVS and KAI) via email. Significant new 
information on ongoing serious adverse events should be provided promptly. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 55 of 789.4 Emergency procedure for unblinding
For this study, the subject and the psychometrician/designee will be blinded. Neither the RenewTM NCP-
5 operator nor the PI will be blinded. The psychometrician/designee administering all cognitive tests 
should be blinded. There does not seem to be any reason that the subject or psychometrician will be 
unblinded in the event of a serious adverse event. Only the investigator, who is unblinded, will need to 
assess what intervention the subject may need or whether the subject can continue in the study.  
9.5 Instructions for completing adverse effect case report forms
Each AE is to be reported on the AE CRF provided. Refer to the CRF or to the CRF Completion Guidelines 
for details.
10.ADMINISTRATIVE PROCEDURES
10.1 Changes to the protocol
Any change to this protocol will be made by means of a protocol amendment approved by Renew 
Research, LLC. Any changes that affect patient safety or welfare must be submitted to the relevant IRB 
for approval before implementation.  
If the investigator believes an immediate change to the protocol is necessary for safety reasons and the 
change is implemented by him/her, Renew Research, LLC should be notified immediately and the IRB 
should be informed within 10 working days.
10.2 Monitoring procedures
During the course of the study, remote and onsite monitoring may be used to obtain a reasonable 
assurance of data quality and proper study implementation. If the study monitor visits the clinical sites, 
they may review any or all relevant study records for completeness, protocol adherence, and 
compliance to investigational device Good Clinical Practice (GCP). The study monitor may also review 
CRF data against the source documents at the study sites. Therefore, the study monitor must be granted 
access to relevant clinic and hospital records in order to review consistency with the CRF. 
All monitoring will be linked to a signal-based process using critical data points and other pertinent 
factors. Instances of missing or uninterpretable data may be discussed with the Investigator or site 
staff for resolution.
11.STATISTICAL CONSIDERATIONS 
A separate Adaptive Design Report (ADR), presented in Appendix A1 details the primary outcome 
analysis and procedures. The ADR contains the plan for sample size consideration and the features of 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 56 of 78the study design. The adaptive statistical analyses will be performed using commercial software 
acceptable to FDA. They describe how the primary outcome measure will be evaluated during interim 
analyses, which will begin when 100 patients have been randomized. Subsequent interim analyses are 
scheduled after every additional 25 subjects are randomized. In total, there are 7 analyses possible, 
which includes 6 interim analyses and the final analysis at 250 subjects, unless the study is stopped for 
success or futility before that. 
Appendix A2  consists of the Adaptive Design report for the secondary outcome analysis of the ADL and 
ADAS-Cog14. As outlined above, a key secondary endpoint for this study is the change from baseline in 
the ADCS-ADL, also averaged across measurements taken at 12, 18, and 24 weeks after randomization.  
The purpose of this document is to pre-specify the Bayesian analysis of this endpoint.  
Appendix B  outlines the Statistical Analysis Plan (SAP),  including the plans for analysis of the remaining 
secondary and exploratory endpoints selected for the study.  
12.DOCUMENT RETENTION
The investigator must maintain source documents for each patient in the study. Source documents will 
include demographic and all medical information, including laboratory data, ECGs, and physical 
examinations. The investigator must also retain the original signed informed consent form for each 
patient.
The following documents related to the study must be retained by the investigator for as long as needed 
to comply with national and international regulations after discontinuing clinical development or after 
the last marketing approval: all source documents and laboratory records; CRF copies; patient informed 
consent forms; IRB approvals for the study protocol, informed consent forms, and all amendments; 
Investigator’s Agreement; any other relevant study documentation.
Renew Research, LLC will notify the investigator(s) when the study-related records are no longer 
required. The investigator's signature on the protocol constitutes his/her agreement with these 
document retention procedures.
13.DATA FLOW 
See Figure 3 , below, for a summary diagram of data flow in this trial. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 57 of 78Figure 3: RenewTM NCP-5 - 1001 Data Flow 
13.1 Source Data, Record Keeping, Handling, and Retention at the Sites
The source data for this study includes data collected at the site based on the protocol defined 
standardized assessments and CRFs, as well as electronic data for central labs and imaging. The 
investigators and authorized, trained site staff will maintain appropriate data to ensure adherence to 
the protocol, regulations, Manual of Procedures (MoP), and any other policies. Subjects at the site will 
be assigned a unique Participant ID that will be used to anonymize the subjects in the source data, 
record files and the commercial EDC System OpenClinica Enterprise ™©(OC EDC) throughout the study. 
A clinical site master list with participant names, contact information, and study identifiers will be stored 
locally at each of the sites for that site only.  
Site study staff may enter data obtained at the study visit directly into the eCRFs of the OC EDC system. 
For these data elements, the eCRF is the source. This direct entry of data can eliminate errors by not 

Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 58 of 78using a paper transcription step before entry into the eCRF. In the event that immediate access to the 
OC EDC is not available or if the site prefers to record data on paper source, data recorded on paper 
source will be used and then will be transcribed into the eCRFs (see Figure 3 ). Authorized, uniquely 
credentialed study personnel will be given secure access to the OC EDC system to review data as 
necessary for proper decision-making, data management and signoffs. 
The paper source data and records will be housed by the clinical site investigators as required by FDA 
IDE regulations 21 CFR 812.140. The investigators will be responsible for completeness and accuracy of 
documented data and records at their site to support study protocol adherence, review and audit. 
Enforcement will be carried out by regular internal audits and routine monitoring visits to verify that all 
processes are followed and required documentation is created and collected. 
It is each clinical site Investigator’s responsibility, by FDA regulation (21 CFR §812.140(d)), to retain 
essential study documents for at least two years after the study is completed. Study completion is 
defined as a time following final database closure and is to be determined by agreement between the 
Data Coordinating Center (DCC) and Renew.  
13.2 Data Transmission, Data Handling, Storage, Retention and Archiving at DCC
Data transmission starts with the site study team review of the participant source documents, if used, to 
ensure data is accurate and complete. Site staff will enter data into the OC EDC (described in Figure 3 ). 
The lab electronic files will be uploaded by the central lab study team, with the proper user name and 
password assigned to each team member, to the sFTP server hosted at the DCC.  
OpenClinica (OC) Enterprise ™© EDC System
Data collected during a study visit will be directly entered onto eCRFs using OC EDC system. As a backup 
procedure, data recorded on the paper source by the site study staff will be transcribed by the site study 
staff onto eCRFs utilizing OC EDC for Web-based remote data entry and storage. OC EDC has a secure, 
robust and scalable technology infrastructure developed using the Java J2EE framework and relies on 
commercial database servers. It is validated according to 21 CFR 11, and is also CDISC compliant. OC EDC 
is an enhanced, fully validated build that is ideal for mission-critical settings. Study users will access OC 
EDC with password protection. In the OC EDC, Study Subjects will be identified only by the unique 
Participant ID assigned to them. OC EDC will not include personal identifiers, as required by HIPAA.  
The OC EDC system offers modules to help the study team continuously review and monitor the data 
over the course of the clinical trial. When Investigator signoffs cannot be accomplished on source paper 
documents, Investigator signoffs will be executed electronically. 
The Source Data Verification (SDV) feature helps study monitors track their evaluations to assess if the 
study data are complete, accurate, and verifiable. Rules for edit checks, logic errors and form navigation 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 59 of 78are centered on key data fields such as dates, quantitative measures and other critical fields that can be 
corrected in real-time as data are entered. In addition, the DCC generated and Renew-approved queries 
can be entered and managed through the OC EDC Notes and Discrepancy module centrally. Data 
managers, monitors and site staff are able to manage data clarifications/queries regarding data entered 
into the EDC via the website. The embedded, real-time edits and queries result in time and cost 
efficiencies in data clean up and production of the final data sets. DCC will work with Renew to create 
and maintain user accounts for those who will require study EDC database access. The Manual of 
Procedures (MoP) and Data Management Plan (DMP) will outline data management activities and the 
details of data clarification and resolution.  
After the last participant visit is entered, data is reviewed at DCC and/or by a Study Monitor, and eCRFs 
are set to complete, a final batch OCEDC system edit run will be done to ensure all queries and 
discrepancies have been addressed. Issues that cannot be resolved are described in a Memo To File and 
attached to any analyses. Renew and DCC will review data in tables and listings. The DCC will notify 
Renew that it considers the database ready for lock. An approval signature by Renew will be obtained 
prior to study database lock. The DCC will perform final database lock procedures per SOP. At the end of 
the study, all study data and materials requested by Renew will be sent, along with a packing document 
that identifies as specifically as possible, the contents of the shipment.  
Secure File Transfer Protocol (sFTP) system  
The DCC will set up a secure File Transfer Protocol (sFTP) system for data transmission for the study, 
provide the sites and central lab with access to upload data and files and other study components and 
resource centers with access to download data and files. Transmission specifications and schedules will 
be documented and approved by Renew. External data will be reviewed and reconciled to ensure file 
integrity, completeness, and correctness. The DCC team will document the data format, receipt process, 
and schedule for receipt in writing, and both the sites and DCC will sign off on this mutual Data 
Transmission Agreement. The process will be quality assured with test data prior to the first data 
transfer. 
Secure sockets layer (SSL) certificates will be used to provide for encrypted and secure communications 
between the DCC, Sites, Central lab and other study components. This encryption minimizes the 
likelihood of interception or modification of data during transmission. DCC’s network infrastructure 
(internal and external systems) is protected from the public Internet by various mechanisms including, 
but not limited to, firewalls (with restrictive policies in place), virtual private network (VPN) endpoints 
and software as well as antivirus and malware detection software. Certain aspects of the logs detailing 
action within the protection systems are collected and reviewed daily. For further protection against 
disaster or loss of data, all data will be backed up daily.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 60 of 78Anonymized site participant data will be received by the DCC through the sFTP. All original transmissions 
will be stored electronically in a secure server on the DCC network. Any problems identified during the 
upload and transmission process will be reported back to the sites for correction or clarification. The 
process for addressing data discrepancies with sites will be determined in coordination with other study 
components during study set-up. The data transmitted to and stored on DCC server will be automatically 
coded with the assigned participant identification number. No personal identifiers will be associated 
with these data.  
Study Datasets 
DCC will provide a SAS data set that integrates the final study data in the OCEDC system and the sFTP. 
The data set will conform to Renew specifications.  
All records created by or received by DCC, will be retained for as long as they are required to meet the 
contractual, legal, regulatory, administrative, financial and operational requirements of DCC. The media 
used to transfer electronic files and study data will be discussed and documented in a study closeout 
plan that will be prepared as the study progresses. The necessary security measures will be taken for 
file/data security and integrity during preparation and transmission these files. A memo detailing the 
transfer of responsibility for study documentation will be prepared by the DCC and signed off by Renew 
prior to the shipment of material to Renew.  
14.AUDITING PROCEDURES
In addition to routine monitoring, Renew Research, LLC or its designee may conduct audits of clinical 
research activities to assess regulatory compliance. A regulatory authority may also conduct an 
inspection. If a regulatory authority requests an inspection, the investigator must inform Renew 
Research, LLC immediately that this request has been made.
15.PUBLICATION OF RESULTS
As a multicenter study, the initial publications such as initial manuscripts, abstracts, and presentations 
reporting interim and final results for the study will be initiated per the prior agreed upon publication 
policy between Renew Research, LLC and the site’s executed Clinical Trial Agreement. Manuscripts will 
be submitted to appropriate scientific journals, professional publications, and major medical meetings. 
All clinical sites and investigators contributing data to the study will be listed in an Appendix to the 
manuscript. Following release of the initial multicenter publication, investigators may prepare 
independent publications for publication review. Renew Research, LLC has the right to require any 
confidential information including chemical structures and chemical names to be excluded from 
publication.
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 61 of 7815.1 Disclosure and C onfidentiality
By signing the protocol, the investigator agrees to keep all information provided by Renew Research, LLC 
in strict confidence and to request similar confidentiality from his/her staff and the IRB. Study 
documents provided by Renew Research, LLC (protocols, investigators' brochures, CRFs, and other 
material) will be stored appropriately to ensure their confidentiality. The information provided by 
Renew Research, LLC to the investigator may not be disclosed to others without direct written 
authorization from RenewTM Research, LLC, except to the extent necessary to obtain informed consent 
from patients who wish to participate in the trial.
16.DISCONTINUATION OF STUDY
Renew Research, LLC reserves the right to discontinue any study under the conditions specified in the 
clinical trial agreement.
17.ETHICS AND GOOD CLINICAL PRACTICE
For all sites located in the United States and its territories, this study must be carried out in compliance 
with the protocol and the principles of GCP, as described in: Title 21 Code of Federal Regulations (CFR) 
dealing with investigational device studies (including 21 CFR Parts 50 and 56 concerning informed 
consent and IRB regulations ). For investigational sites located outside of the United States and its 
territories this study must be carried out in compliance with the protocol and the appropriate 
regulatory authority, such as ICH or MHRA; as well as any other International requirements or 
relevant mandates.
The investigator agrees when signing the protocol to adhere to the instructions and procedures 
described in it and thereby to adhere to the principles of GCP to which it conforms.
17.1 Institutional Review Board/Independent Ethics Committee
Before implementing this study, the protocol, the proposed informed consent form, other information 
provided to patients, and advertising must be reviewed by a properly constituted IRB. A signed and 
dated statement that the protocol and informed consent have been approved by the IRB must be given 
to Renew Research, LLC before study initiation. The name and occupation of the chairman and the 
members of the IRB must be supplied to Renew Research, LLC. Any amendments to the protocol, other 
than administrative ones, must be approved by this committee.
The investigator must explain to each patient (or legally authorized representative) the nature of the 
study, its purpose, the procedures involved, the expected duration, the potential risks and benefits 
involved, and any discomfort it may entail. Each patient must be informed that participation in the study 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 62 of 78is voluntary and that he/she may withdraw from the study at any time and that withdrawal of consent 
will not affect his/her subsequent medical treatment or relationship with the treating physician.
This informed consent should be given by means of a standard written statement, written in 
nontechnical language. The patient should read and consider the statement before signing and dating it, 
and should be given a copy of the signed document. If the patient cannot read or sign the documents, 
oral presentation may be made or signature given by the patient's legally appointed representative, if 
witnessed by a person not involved in the study, mentioning that the patient could not read or sign the 
documents. No patient can enter the study before his/her informed consent has been obtained. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 63 of 7818.REFERENCE LIST
Ahdidan J, Raji CA, DeYoe EA, Mathis J, Noe KØ, Rimestad J, Kjeldsen TK, Mosegaard J, Becker JT, Lopez 
O. Quantitative neuroimaging software for clinical assessment of hippocampal volumes on MR 
imaging. Journal of Alzheimer's Disease. 2016 Jan 1;49(3):723-32. 
Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-
labeled magnetic resonance imaging. Ann Neurol . 2000;47(1):93-100. 
Androsova LV, Mikhailova NM, Zozuilia SA, et al. Inflammatory markers in Alzheimer’s disease and 
vascular dementia. Zh Nevrol Psikhiatr Im S Korsakova . 2013;113(2):49-53. 
Applebaum RM, Kasliwal R, Tunick PA, et al. Sequential external counterpulsation increases cerebral 
and renal blood flow. Am Heart J . 1997;133(6):611-615.  
Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease 
to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. 
Lancet Neurol.  2016;15(9):934-943.  
Bangen KJ, Preis SR, Delano-Wood L, et al. Baseline White Matter Hyperintensities and Hippocampal 
Volume are Associated With Conversion From Normal Cognition to Mild Cognitive Impairment in the 
Framingham Offspring Study. Alzheimer Dis Assoc Disord . 2018;32(1):50-56.  
Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer’s 
disease. Neurobiology of Aging . 2009;30(11):1711-1723. 
Barry E, Galvin R, Keogh C, Horgan F, Fahey T. Is the Timed Up and Go test a useful predictor of risk 
of falls in community dwelling older adults: a systematic review and meta-analysis. BMC Geriatrics. 
2014; 14. 
Barsness GW. Enhanced External Counterpulsation in Unrevascularizable Patients. Curr Interv Cardiol 
Rep. 2001;3(1):37-43. 
Belz GG. Elastic properties and Windkessel function of the human aorta. Cardiovasc Drugs Ther . 
1995;9(1):73-83. 
Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM. Vascular disease and risk factors, rate 
of progression, and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol . 2006;19(2):78-82.  
Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations in 
vascular cognitive impairment. Stroke . 2009;40(3 Suppl):S48-52.  
Bohannon RW. Reference values for the Timed Up and Go Test: A descriptive meta-analysis. Journal 
of Geriatric Physical Therapy. 2006;29(2):64-8. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 64 of 78Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial 
function in patients with symptomatic coronary artery disease. J Am Coll Cardiol . 2003;41(10):1761-
1768. 
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol . 
1991;82(4):239-259. 
Brain Changes Speak Volumes About Normal Aging and Dementia. Alzforum. 
https://www.alzforum.org/news/research-news/brain-changes-speak-volumes-about-normal-aging-
and-dementia. Updated June 7, 2013. Accessed on March 4, 2018. 
Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral 
artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. 
Circulation . 2010;122(16):1612-1620. 
Bredesen DE, Amos EC, Canick J, Ackerley M, Raji C, Fiala M, Ahdidan J. Reversal of cognitive decline 
in Alzheimer's disease. Aging (Albany NY). 2016 Jun;8(6):1250. 
Brickman AM, Zahodne LB, Guzman VA, et al. Reconsidering harbingers of dementia: progression of 
parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging . 
2015;36(1):27-32. 
Bron EE, Steketee RM, Houston GC, Oliver RA, Achterberg HC, Loog M, Swieten JC, Hammers A, 
Niessen WJ, Smits M, Klein S. Diagnostic classification of arterial spin labeling and structural MRI in 
presenile early stage dementia. Human brain mapping. 2014 Sep 1;35(9):4916-31. 
Buschmann EE, Utz W, Pagonas N, et al. Improvement of fractional flow reserve and collateral flow by 
treatment with external counterpulsation (Art.Net.-2 Trial). Eur J Clin Invest . 2009;39(10):866-875. 
Campbell AR, Satran D, Zenovich AG, et al. Enhanced external counterpulsation improves systolic 
blood pressure in patients with refractory angina. Am Heart J . 2008;156(6):1217-1222. 
Casey DP, Beck DT, Nichols WW, et al. Effects of enhanced external counterpulsation on arterial 
stiffness and myocardial oxygen demand in patients with chronic angina pectoris. Am J Cardiol.
2011;107(10):1466-1472 
Catanho M, Sinha M, Vijayan V. Model of Aortic Blood Flow Using the Windkessel Effect. BENG 221 – 
Mathematical Methods in Bioengineering Report . October 25, 2012. 
Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ. Hemorheological mechanisms in Alzheimer’s disease. 
Microcirculation . 2007;14(6):627-634. 
Chen S, Bu X, Jin W, et al. Altered peripheral profile of blood cells in Alzheimer disease: A hospital-
based case-control study. Medicine . 2017;96:21 (e6843) 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 65 of 78Ciesielska N, Sokolowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kedziora-Kornatowska K. Is the 
Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination 
(MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. 
Psychiatr Pol. 2016 Oct 31;50(5):1039-52.  
Coutu JP, Goldblatt A, Rosas HD, Salat DH. Alzheimer's Disease Neuroimaging I. White Matter Changes 
are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's 
Disease. J Alzheimers Dis . 2016;49(2):329-342.  
Coutu JP, Lindemer ER, Konukoglu E, Salat DH. Alzheimer's Disease Neuroimaging I. Two distinct 
classes of degenerative change are independently linked to clinical progression in mild cognitive 
impairment. Neurobiol Aging . 2017;54:1-9.  
Cummings, J. L. (1997). The Neuropsychiatric Inventory: Assessing psychopathology in dementia 
patients. Neurology, 48, S10-S16. 
Dai W, Lopez OL, Carmichael OT, et al. Mild cognitive impairment and Alzheimer disease: patterns of 
altered cerebral blood flow at MR imaging. Radiology . 2009;250:856–866. 
Daulatzai, MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological 
modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s disease. J Neurosci 
Res. 2017;95(4):943-972. 
Dementia Research and Clinical Trials: Alzheimer’s Disease Research Centers. National Institute on 
Aging. https://www.nia.nih.gov/health/alzheimers-disease-research-centers. Accessed March 4, 
2018.  
Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the 
pathogenesis of Alzheimer's disease—a review of endothelium-mediated mechanisms and ensuing 
vicious circles. Neurobiology of disease. 2015 Oct 1;82:593-606. 
Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical 
comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci . 2002;57(3):M173-177.  
Duncan PW, Weiner DK, et al. Functional reach: a new clinical measure of balance. Journal of 
Gerontology. 1990;45(6): M192-197. 
Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves 
memory. Proc Natl Acad Sci U S A . 2011;108(7):3017-3022. 
Fisher, et al. Machine learning for comprehensive forecasting of Alzheimer’s Disease progression. 
Scientific Reports . 2019; 9:13622. 
Fernando MS, Simpson JE, Matthews F, et al. Function MRCC, Ageing Neuropathology Study G. White 
matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from 
chronic hypoperfusion injury. Stroke.  2006;37(6):1391-1398.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 66 of 78Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading cognitive 
state of patients for the clinician. J Psychiatr Res . 1975;12(3):189-198. 
Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy 
study. Arch Pathol Lab Med . 2004;128(1):32-38. 
Goff DC, Lloyd-Jones DM, Bennet G, et al. 2013 ACC/AHA Guideline on the Assessment of 
Cardiovascular Risk. A Report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. Circulation . 2013;01.cir.0000437741.48606.98 
Gorbach T, Pudas S, Lundquist A, et al. Longitudinal assessment between hippocampal atrophy and 
episodic-memory decline. Neurobiology of Aging . 2017;51:167-176. 
Gupta A, Watkins A, Thomas P. Coagulation and inflammatory markers in Alzheimer’s and vascular 
dementia. Int J Clin Pract . 2005;59(1):52-57. 
Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, Knopman DS, Mintz A, Rahmim A, 
Sharrett AR, Wagenknecht LE. Association between midlife vascular risk factors and estimated brain 
amyloid deposition. Jama. 2017 Apr 11;317(14):1443-50. 
Gurovich AN, Braith RW. Enhanced external counterpulsation creates acute blood flow patterns 
responsible for improved flow-mediated dilation in humans. Hypertens Res . 2013;36(4)297-305. 
Han JH, Wong KS. Is counterpulsation a potential therapy for ischemic stroke?. Cerebrovascular 
Diseases. 2008;26(2): 97-105. 
Harlein J, Dassen T, Halfens RJ, Heinze C. Fall risk factors in older people with dementia or cognitive 
impairment: a systematic review. Journal of Advanced Nursing. 2009 May 65(5):922-33. 
Hays CC, Zlatar ZZ, Wierenga CE. The Utility of Cerebral Blood Flow as a Biomarker of Preclinical 
Alzheimer's Disease. Cell Mol Neurobiol . 2016;36(2):167-179. 
Hebscher M, Levine B, Gilboa A. The precuneus and hippocampus contribute to individual 
differences in the unfolding of spatial representations during episodic autobiographical memory. 
Neuropsychologia. 2017 Mar 30. 
Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, 
Boccardi M. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of 
hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. 
Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014 Jul 1;10(4):421-9.
Hilz MJ, Werner D, Marthol H, Flachskamp FA, Daniel WG. Enhanced external counterpulsation 
improves skin oxygenation and perfusion. Eur J Clin Invest . 2004;34(6):385-391. 
Hirao K, Ohnishi T, Hirata Y, et al. The prediction of rapid conversion to Alzheimer's disease in mild 
cognitive impairment using regional cerebral blood flow SPECT. Neuroimage . 2005;28:1014–1021. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 67 of 78Hui JCK, Lawson WE, Barness GW. EECP in the treatment of endothelial dysfunction: Preventing 
progression of cardiovascular disease. J Geriatric Cardiol . 2010;7(2):80-87.  
Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal 
neuropathology in typical aging and dementia. Neurology . 2002;58(5):750-757. 
Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with 
clinical disease progression in AD. Neurology . 2004;62(4):591-600.  
Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic 
trial of milameline for AD. Neurology . 2003;60(2):253-260. 
Jerca L, Jerca O, Gabriela M, Constantinescu I, Lupusoru R. Mechanism of action and biochemical 
effects of nitric oxide (NO). J Prev Med . 2002;10:35-45. 
Kat-Leurer M, Fisher I, Et al. Reliability and validity of the modified functional reach test at the sub-
acute stage post-stroke. Journal of Disability and Rehabilitation. 2009;31(3): 243-248. 
Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular 
dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2017 Jul;18(7):419. 
Kozdag G, Iseri P, Gokce G, et al. Treatment with enhanced external counterpulsation improves 
cognitive functions in chronic heart failure patients. Turk Kardiyol Dern Ars.  2013;41(5):418-428.  
Kramer-Ginzberg E, Mohs RC, Aryan M, et al. Predictors of course for Alzheimer’s patients in a 
longitudinal study: A prelimary report. Psychopharmacology Bulletin . 1988;24:458-462. 
Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer’s disease, Parkinson’s 
disease with and without dementia, and in vascular dementia An MRI Study. Neurology . 
1996;46(3):678-681. 
Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment 
to Alzheimer disease. Neurology.  2011;76(17):1485-91. 
Li WP, Yao ZB, Yang WJ, Chen YC, Peng WH, Hu P. Study of the external counterpulsation (ECP) therapy 
for senile dementia of the Alzheimer's type (SDAT). Chin Med J (Engl) . 1994;107(10): 755-760. 
Lindemer ER, Salat DH, Smith EE, Nguyen K, Fischl B, Greve DN. Alzheimer's Disease Neuroimaging I. 
White matter signal abnormality quality differentiates mild cognitive impairment that converts to 
Alzheimer's disease from nonconverters. Neurobiol Aging . 2015;36(9):2447-2457. 
Longoni G, Rocca MA, Pagani E, Riccitelli GC, Colombo B, Rodegher M, Falini A, Comi G, Filippi M. 
Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. Brain 
Structure and Function. 2015 Jan 1;220(1):435-44. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 68 of 78Luis CA, Keegan AP, Mullan M. Cross validation of the Montreal Cognitive Assessment in community 
dwelling older adults residing in the Southeastern US. International journal of geriatric psychiatry. 
2009 Feb 1;24(2):197-201. 
Lye TC, Piguet O, Grayson DA, et al. Hippocampal size and memory function in the ninth and tenth 
decades of life: the Sydney Older Persons Study. J Neurol Neurosurg Psychiatry . 2004;75(4):548-554.  
Michel T, Feron O. Nitric oxide synthases: Which, where, how and why? J Clin Invest . 1997; 100(9): 
2146-2152. 
Moriarty PM, Badawi AH, Lepping RJ, et al. External  Counterpulsation Therapy for Patients with Mild 
Cognitive Impairment. Austin J Clin Med. 2016;3(1):1029. 
Nasreddine Z, Phiillips NA 2005, Apr J Amer Ger Soc 53(4) 695-99 Montreal Cognitive Assessment: a 
brief screen tool.  
Neville, J. et al. Development of a unified clinical trial database for Alzheimer’s disease. Alzheimer’s & 
Dementia: journal Alzheimer’s Assoc . 2015; 11: 1212–1221. 
Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration 
in dementia and Alzheimer's disease. Biochim Biophys Acta. 2016;1862(5):887-900.  
Pagonas N. Effect of external counterpulsation on coronary collateral artery growth and myocardial 
blood flow in patients with stable coronary disease [dissertation]. Berlin: Universitätsmedizin Berlin; 
2011. 
Paillard T. Preventive effects of regular physical exercise against cognitive decline and the risk of 
dementia with age advancement. Sports Med Open . 2015;1(1):20. 
Papaioannou TG, Stefanadis C. Vascular wall shear stress: Basic principles and methods. Hellenic J 
Cardiol . 2005; 46: 9-15.  
Peters R, Beckett N, Fagard R, et al. Increased pulse pressure linked to dementia: further results from 
the Hypertension in the Very Elderly Trial – HYVET. J Hypertens . 2013;31(9):1868-1875. 
Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, Galluzzi S, Marizzoni M, Frisoni GB. 
Brain atrophy in Alzheimer’s disease and aging. Ageing research reviews. 2016 Sep 1;30:25-48 
Pohlack ST, Meyer P, Cacciaglia R, Liebscher C, Ridder S, Flor H. Bigger is better! Hippocampal volume 
and declarative memory performance in healthy young men. Brain Structure and Function. 2014 Jan 
1;219(1):255-67. 
Presecki P, Muck-Seler D, Mimica N, et al. Serum lipid levels in patients with Alzheimer’s disease. Coll 
Antropol . 2011;35 Suppl 1:115-120. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 69 of 78Qualiﬁcation opinion of low hippocampal volume (atrophy) by MRI for use in clinical trials - in pre-
dementia stage of Alzheimer’s disease. European Medicines Agency. 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/
2011/10/WC500116264.pdf. Published October 10, 2011. Accessed on March 3, 2018. 
Rabinovici GD, Carrillo MC, Forman M, et al. Multiple comorbid neuropathologies in the setting of 
Alzheimer's disease neuropathology and implications for drug development. Alzheimers Dement (N 
Y). 2017;3(1):83-91.  
Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a 
study of a five-year change. Neurology . 2004;62(3)433-438.  
Renew Group Private, Ltd. RenewTM NCP-5 External Counterpulsation System Traditional 501(k) 
Premarket Notification. July 23, 2015. 
Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral blood flow in Alzheimer’s disease. Vascular 
Health and Risk Management . 2012;8(1):599-611. 
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry . 1984; 
141:1356-1364. 
Sabayan B, Jansen S, Oleksik AM, et al. Cerebrovascular hemodynamics in Alzheimer’s disease and 
vascular dementia: a meta-analysis of transcranial Doppler studies. Ageing Res Rev . 2012;11(2):271-
277. 
Schmidt MF, Storrs JM, Freeman KB, et al. A comparison of manual tracing and FreeSurfer for 
estimating hippocampal volume over the adult lifespan. Hum Brain Mapp . 2018 ;00:1–14.
Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Austrian Stroke Prevention S. Progression of 
cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study.  Lancet. 
2003;361(9374):2046-2048.  
Schmidt R, Scheltens P, Erkinjuntti T, et al. White matter lesion progression: a surrogate endpoint for 
trials in cerebral small-vessel disease. Neurology. 2004;63(1):139-144.  
Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer’s disease in 
relation to ApoE genotype and biomarkers. Brain . 2009;132(Pt 4):1067-1077. 
Shecter M, Matetzky S, Feinberg MS, Chouraqui P, Rotstein Z, Hod H. External counterpulsation 
therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol . 
2003;42(12):2090-2095. 
Silbert LC, Dodge HH, Perkins LG, et al. Trajectory of white matter hyperintensity burden preceding 
mild cognitive impairment. Neurology . 2012;79(8):741-747.  
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 70 of 78Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer’s disease 
pathology. Neurology . 2003;61(4):487-492.  
Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, Lamb BT, Montine TJ, 
Nedergaard M, Schaffer CB, Schneider JA. Vascular contributions to cognitive impairment and 
dementia including Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's 
Association. 2015 Jun 1;11(6):710-7. 
Smith MM, Chen PC, Li CS, Ramanujam S, Cheung AT. Whole blood viscosity and microvascular 
abnormalities in Alzheimer’s Disease. Clin Hemorheal Microcirc.  2009;41(4):229-239. 
Strickland S. Blood will out: vascular contributions to Alzheimer’s disease. The Journal of clinical 
investigation. 2018 Feb 1;128(2):556-63. 
Squire, L. R. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. 
Psychol Rev . 1992;99(2):195-231. 
Sun ZW, Zhu YX, Liu HY, et al. Decreased cerebral blood flow velocity in apolipoprotein E epsilon4 
allele carriers with mild cognitive impairment. European Journal of Neurology . 2007;14(2):150-155. 
Thaker AA, Weinberg BD, Dillon WP, Hess CP, Cabral HJ, Fleischman DA, Leurgans SE, Bennett DA, 
Hyman BT, Albert MS, Killiany RJ. Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem 
Neurofibrillary Tangles and Amyloid Pathology. American Journal of Neuroradiology. 2017 May 
1;38(5):961-5. 
Turcato G, Serafini V, Dilda A, et al. Red blood cell distribution width independently predicts medium-
term mortality and major adverse cardiac events after an acute coronary syndrome. Ann Transl Med . 
2016;4(13):254. 
Trzepacz PT, Hochstetler H, Yu P, Castelluccio P, Witte MM, Degenhardt EK, Alzheimer''s Disease 
Neuroimaging Initiative. Relationship of hippocampal volume to amyloid burden across diagnostic 
stages of Alzheimer's disease. Dementia and geriatric cognitive disorders. 2016;41(1-2):68-79. 
U.S. Food and Drug Administration Center for Devices & Radiological Health. Clinical Considerations 
for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression 
and Clinical Outcomes: Guidance for Industry and Food and Drug Administration Staff. Rockville, MD: 
FDA; 2016. 
Van Es AC, van der Flier WM, Box FM, et al. Carotid and basilar artery wall shear stress in Alzheimer’s 
disease and mild cognitive impairment. Dement Geriartr Cogn Disord . 2009;28(3):220-224. 
Van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, van Duijn CM. The effect of APOE 
and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-
based cohort study. The Lancet Neurology. 2018 Mar 16 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 71 of 78Vecchio F, Miraglia F, Piludu F, Granata G, Romanello R, Caulo M, Onofrj V, Bramanti P, Colosimo C, 
Rossini PM. “Small World” architecture in brain connectivity and hippocampal volume in Alzheimer’s 
disease: a study via graph theory from EEG data. Brain imaging and behavior. 2017 Apr 1;11(2):473-
85. 
Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl 
J Med.  2003;348(25): 2508-2516. 
Walsh, et al. Generating Digital Twins with Multiple Sclerosis Using Probabilistic Neural Networks. 
bioRxiv:934679, https://doi.org/10.1101/2020.02.04.934679 
Wang HX, Karp A, Winblad B, Fratiglioni L. Late-life engagement in social and leisure activities is 
associated with decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J 
Epidemiol . 2002;155(12):1081-1087. 
Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S. What are white matter hyperintensities made 
of? Relevance to vascular cognitive impairment. J Am Heart Assoc . 2015;4(6):001140.  
Werner D, Marthol H, Brown CM, Daniel WG, Hilz MJ. Changes of cerebral blood flow velocities during 
enhanced external counterpulsation. Acta Neurol Scand.  2003; 107: 405-411.  
Ylikoski R, Jokinen H, Andersen P, et al. Comparison of the Alzheimer’s Disease Assessment Scale 
Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals 
with different degrees of white matter changes. The LADIS Study. Dement Geriatr Cogn 
Disord. 2007;24(2):73-81. 
Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, 
Christensen JJ, Morris JC. In vivo detection of microstructural correlates of brain pathology in 
preclinical and early Alzheimer Disease with magnetic resonance imaging. NeuroImage. 2017 Mar 
1;148:296-304. 
Zhang Y, He X, Chen X, et al. Enhanced external counterpulsation inhibits intimal hyperplasia by 
modifying shear stress responsive gene expression in hypercholesterolemic pigs. Circulation . 
2007;116(5):526-534. 
Zhang N, Gordon ML, Goldberg TE. Cerebral blood flow measured by arterial spin labeling MRI at 
resting state in normal aging and Alzheimer’s disease. Neuroscience & Biobehavioral Reviews. 2017 
Jan 1;72:168-75. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
Confidentiality Statement 
The confidential information in this document is provided to you as an investigator or consultant for review by you, 
your staff, and the applicable Institutional Review Board. Your acceptance of this document constitutes agreement 
that you will not disclose the information contained herein to others without written authorization from the 
sponsor. 
Page 72 of 78APPENDIX A1: Adaptive Design Report (Primary Outcome) 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001 April 10, 2020 
APPENDIX A2: ADCS-ADL and ADAS-14 Secondary Outcome Analysis 
Renew Research, LLC                                                      Statistical Analysis Plan, Version 1.0 
Protocol No.: RenewTM NCP-5-1001                                                                Date Issued: 16APR2020 
APPENDIX B: Statistical Analysis Plan 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
APPENDIX C: Health Resource Utilization (HRU) 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
APPENDIX D: Investigator Brochure 
This will be supplied as a separate attachment to sites. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
APPENDIX E: Training Manual 
This will be supplied as a separate attachment to sites. 
Renew Research, LLC Protocol v. 3.1 
Protocol #: RenewTM NCP-5 -1001                                                             April 22, 2020 
APPENDIX F:  Device Inspection Checklist 
This will be supplied as a separate attachment to sites. 